,PageNo,Text
0,page_0,"Global Clinical Development -General Medicine CIGE025/O malizumab Clinical Trial Protocol CIGE025E2305 / NCT03328897 A multicenter, randomized, double -blind, placebo - controlled phase III study to evaluate the efficacy and safety of Xolair® (omalizumab ) in Chinese patients w ith chronic spontaneous urticaria w ho remain symptomatic despite antihistamine treatment Document type: Clinical Trial Protocol EUDRACT number: Not applicable Version number: 00 (Original Protocol) Clinical trial phase: III Release date: 10-Aug-2016 Property of Novartis Confidential May not be used, divulged, pu blished, or otherwise disclosed without the consent of Novartis Clinical Trial Protocol Template Version 3.1 (February 2016 )"
1,page_1,"Novartis Confidential Page 2 Clinical Trial Protocol (Version 00 ) Protocol No. CIGE025E2305 Table of contents Table of contents ................................................................................................................. 2 List of tables ........................................................................................................................ 5 List of figures ...................................................................................................................... 5 List of abbreviations ............................................................................................................ 6 Glossary of terms ................................................................................................................. 8 Protocol summary ................................................................................................................ 9 1Introduction ....................................................................................................................... 13 1.1 Background ............................................................................................................ 13 1.2 Purpose .................................................................................................................. 14 2 S tudy objectives and endpoints ......................................................................................... 15 2.1 Objectives and related endpoints ........................................................................... 15 3Investigational plan ........................................................................................................... 17 3.1 Study design ........................................................................................................... 17 3.2 Rationale for stud y design ..................................................................................... 19 3.3 Rationale for dose/regimen, route of administration and duration of treatment.... 19 3.4 Rationale for choice of comparator ....................................................................... 21 3.5 Purpose and timing of interim anal yses/design adaptations .................................. 21 3.6 Risks and benefits .................................................................................................. 21 4Population .......................................................................................................................... 23 4.1 Inclusion criteria .................................................................................................... 24 4.2 Exclusion criteria ................................................................................................... 24 5Treatment ........................................................................................................................... 26 5.1 Study treatment ...................................................................................................... 26 5.1.1 Investigational and control drugs .......................................................... 26 5.1.2 Additional treatment .............................................................................. 27 5.2 Treatment arms ...................................................................................................... 27 5.3 Treatment assignment and randomization ............................................................. 27 5.4 Treatment blinding ................................................................................................. 28 5.5 Treating the patient ................................................................................................ 29 5.5.1 Patient numbering, ................................................................................ 29 5.5.2 Dispensing the stud y drug ..................................................................... 29 5.5.3 Handling of study and additional treatment .......................................... 29 5.5.4 Instructions for prescribing and taking stud y treatment ........................ 30 5.5.5 Permitted dose adjustments and interruptions of study treatment ........ 31 5.5.6 Rescue medication ................................................................................ 31"
2,page_2,Novartis Confidential Page 3 Clinical Trial Protocol (Version 00 ) Protocol No. CIGE025E2305 5.5.7 Concomitant medication ....................................................................... 31 5.5.8 Prohibited medication ........................................................................... 32 5.5.9 Emergency breaking of assigned treatment code .................................. 32 5.6 Study completion and discontinuation ................................................................... 33 5.6.1 Study completion and post -study treatment .......................................... 33 5.6.2 Discontinuation of study treatment ....................................................... 33 5.6.3 Withdrawal of informe d consent ........................................................... 34 5.6.4 Loss to follow -up .................................................................................. 35 5.6.5 Early study termination by the sponsor ................................................. 35 6 Visit schedule and assessments ......................................................................................... 35 6.1 Information to be collected on screening failures .................................................. 39 6.2 Patient demographics/other baseline characteristics ............................................. 39 6.2.1 Tuberculo sis screening and management .............................................. 39 6.2.2 Other baseline characteristics ................................................................ 42 6.3 Treatment exposure and compliance ..................................................................... 42 6.4 Efficacy .................................................................................................................. 42 6.4.1 eDiary assessments ................................................................................ 42 6.4.2 Patient reported outcome assessment .................................................... 45 6.4.3 Appropriateness of efficacy assessments .............................................. 45 6.5 Safety ..................................................................................................................... 45 6.5.1 Physical examination ............................................................................ 45 6.5.2 Vital signs .............................................................................................. 46 6.5.3 Height and weight ................................................................................. 46 6.5.4 Laboratory evaluations .......................................................................... 46 6.5.5 Electrocardiogram (ECG) ..................................................................... 47 6.5.6 Pregnancy and assessments ................................................................... 47 6.5.7 Appropriateness of safety measurements .............................................. 47 47 47 7Safety monitoring .............................................................................................................. 48 7.1 Adverse events ....................................................................................................... 48 7.2 Serious adverse events ........................................................................................... 49 7.2.1 Definition of SAE ................................................................................. 49 7.2.2 SAE reporting ........................................................................................ 50 7.3 Liver safety monitoring ......................................................................................... 51 7.4 Renal safet y monitoring ......................................................................................... 51
3,page_3,"Novartis Confidential Page 4 Clinical Trial Protocol (Version 00 ) Protocol No. CIGE025E2305 7.5 Reporting of stud y treatment errors including misuse/abuse ................................ 51 7.6 Pregnancy reporting ............................................................................................... 52 8Data review and database management ............................................................................. 52 8.1 Site monitoring ...................................................................................................... 52 8.2 Data collection....................................................................................................... 53 8.3 Database management and quality control ............................................................ 53 8.4 Data Monitoring Committee .................................................................................. 54 8.5 Adjudication Committee ........................................................................................ 54 9Data analy sis...................................................................................................................... 54 9.1 Analy sis sets .......................................................................................................... 54 9.2 Patient demographics and other baseline characteristics....................................... 55 9.3 Treatments ............................................................................................................. 55 9.4 Analy sis of the primary variable(s) ....................................................................... 56 9.4.1 Variable(s) ............................................................................................. 56 9.4.2 Statistical model, hy pothesis, and method of anal ysis.......................... 56 9.4.3 Handling of missing values/ce nsoring/discontinuations ....................... 57 9.4.4 Sensitivity analy ses............................................................................... 57 9.5 Analy sis of secondary variables ............................................................................ 57 9.5.1 Efficacy variables.................................................................................. 57 9.5.2 Safety variables ..................................................................................... 61 9.5.3 Resource utilization ............................................................................... 63 9.5.4 Biomarkers ............................................................................................ 63 9.5.5 DNA ...................................................................................................... 63 63 63 9.7 Interim anal yses..................................................................................................... 66 9.8 S ample size calculation .......................................................................................... 66 10Ethical considerations ........................................................................................................ 69 10.1 Regulatory and ethical compliance ........................................................................ 69 10.2 Informed consent procedures................................................................................. 69 10.3 Responsibilities of the investigator and IRB/ IEC.................................................. 70 10.4 Publication of study protocol and re sults............................................................... 70 10.5 Quality Control and Quality Assurance ................................................................. 70 11Protocol a dherence ............................................................................................................ 70 11.1 Protocol amendments ............................................................................................. 71 12References ......................................................................................................................... 71"
4,page_4,Novartis Confidential Page 5 Clinical Trial Protocol (Version 00 ) Protocol No. CIGE025E2305 13Appendi ces........................................................................................................................ 73 13.1 Appendix 1: Clinically notable laboratory values and vital signs ......................... 73 13.2 Appendix 2 Blood log ............................................................................................ 73 13.3 Appendix 3 Dermatology L ife Qualit y Index (DLQI) questionnaire .................... 74 List of tables Table 2 -1 Objectives and related endpoints .......................................................... 15 Table 3-1 Number of stud y drug administrations at Day 1 and at Weeks 4 and 8 ...................................................................................................... 21 Table 5 -1 Prohibited medication ........................................................................... 32 Table 6 -1 Assessment schedule ............................................................................. 36 Table 6 -2 Urticaria Activity Score (UAS) ............................................................. 42 44 44 44 Table 7 -1 Guidance for capturing the stu dy treatment errors including misuse/abuse ......................................................................................... 52 Table 9 -1 Power anal ysis of primary and key secondary endpoints ..................... 67 73 Table 13 -2 Blood log for immunogenicity .............................................................. 73 List of figures Figure 3-1 Study design .......................................................................................... 18 Figure 6 -1 Tuberculosis screening flowchart ......................................................... 40 Figure 9 -1 Testing strategy for primary and secondary endpoints ......................... 59
5,page_5,Novartis Confidential Page 6 Clinical Trial Protocol (Version 00 ) Protocol No. CIGE025E2305 List of abbreviations AE Adverse Event ALT Alanine Transaminase ANCOVA Analysis of covariance AR Autoregressive AST Aspartate Transaminase ATA Anti-Therapeutic A ntibodies AV Atrioventricular BMI Body Mass Index BOCF Baseline Observation Carried Forward BUN Blood Urea Nitrogen CFDA China Food and Drug Administration CI Confidence Interval CPO Countr y Pharma Organization CQA Clinical Quality Assurance CRA Clinical Research Associate CRF Case Report F orm CRO Contract Research Organisation CSU Chronic Spontaneous Urticaria CT Computed Tomography DAR Dose Administration Record DBP Diastolic Blood Pressure DSM Drug Supply Management ECG Electrocardiogram EDC Electronic Data Capture EMA European Medicines Agency EU European Union FAS Full Analysis Set FcεRI Fc Epsilon Receptor I GCP Good Clinical Practice H1AH H1 Antihistamines HSS Health Systems Specialist IB Investigators Brochure ICH International Conference on Harmonization IEC Independent Ethics Committee IgE Immunoglobulin E IgG Immunoglobulin G IN Investigator Notification INH Isoniazid ISS Itch Severity Score IUD Intrauterine Device IUS Intrauterine System J2R Jump to R eference
6,page_6,Novartis Confidential Page 7 Clinical Trial Protocol (Version 00 ) Protocol No. CIGE025E2305 LDH Lactate Dehydrogenase LFT Liver Function Tests LOCF Last Non Missing W eekly Score LSM Least Squares Means LTRA Leukotrine Receptor Antagonist MAR Missed At Random MMRM Mixed Effect Linear Model W ith Repeated Measures MRI Magnetic Resonance Imaging NHS Number of Hives Score PH Proportional Hazard PPD Purified Protein Derivative PRO Patient Reported Outcome PSUR Periodic Safety Update Report QFT QuantiFERON Tuberculosis Gold Test QM Quality Management QTcF Fridericia's Correction Formula RAN Randomized Set RMP Risk Management Plan SAE Serious Adverse Event SAF Safety Set SBP Systolic Blood Pressure SD Standard Deviation SmPC Summary of Product Characteristics SMQ Standardized MedDRA query SOC System Organ Class TB Tuberculosis UNS Unscheduled Treatment Discontinuation Visit US United States US CFR United States Code of Federal Regulations WOC Withdrawl of Consent β-hCG Beta Human Chorionic Gonadotropin
7,page_7,"Novartis Confidential Page 8 Clinical Trial Protocol (Version 00 ) Protocol No. CIGE025E2305 Glossary of terms Assessment A procedure used to generate data required by the study Control drug Drugs (s)used as a comparator to reduce assessment bias, preserve blinding of investigational drug, assess internal study validity, and/or evaluate comparative effects of the investigational drug Dosage Dose of the study treatment given to the patient in a time unit (eg. 100 mg once a day, 75 mg twice a day ) Enrollment Point/time of patient entry into the study at which informed consent must be obtained (e.g. prior to starting any of the procedures descr ibed in the protocol ) Epoch A portion of the study which serves a specific purpose. T ypical epochs are: screening/recruitment, wash -out, treatment, and follow -up Investigational drug The drug whose properties are being tested in the study; this definition is consistent with US CFR 21 Section 312.3 and is synony mous with “investigational new drug” or “investigational medicinal product.” Investigational treatmentAll investigational drug (s)whose properties are being tested in the study as well as their associated treatment controls. This includes any placebos, any active controls, as well as approved drugs used outside of their indication/approved dosage or tested in a fixed combination. Investigational treatment generally does not include protoco l-specified concomitant background therapies when these are standard treatments in that indication Medication pack numberA unique identifier on the label of each investigational drug package Patient/subject ID A unique number assigned to each patient u pon signing the informed consent Protocol A written account of all the procedures to be followed in a trial, which describes all the administrative, documentation, analytical and clinical processes used in the trial. Randomization numberA unique identifier assigned to each randomized patient, corresponding to a specific treatment arm assignment Study drug/ treatmentAny single drug or combination of drugs administered to the patient as part of the required study procedures; includes investigation al drug (s), placebo/comparator active drug run -ins or background therapy UAS7 Sum of daily urticaria activity score (UAS)over 7 days prior to its assessment day. The daily UAS is average of the morning and evening UAS which is a composite score of the number of wheals (hives )andtheintensity of itch. Variable A measured value or assessed response that is determined in specific assessments and used in data analysis to evaluate the drug being tested in the study Weekly itch severity score (ISS)Sum of daily itch scores over 7 days prior to its assessment day. The daily itch score is average of the morning and evening itch scores. The intensity of itch score is recorded on a scale of 0 (none )to 3 (intense/severe ). Withdrawal of consent (WoC)Withdrawal of consent from the study is defined as when a patient does not want to participate in the study any longer, and does not want any further visits or assessments, and does not want any further study related contact, a nd does not allow analysis of already obtained biologic material"
8,page_8,"Novartis Confidential Page 9 Clinical Trial Protocol (Version 00 ) Protocol No. CIGE025E2305 Protocol summary Protocol numberCIGE025E2305 TitleA multicenter, randomized, double -blind, placebo -controlled phase III study to evaluate the efficacy and safety of Xolair®(omalizumab )in Chinese patients with chronic spontaneous urticaria (CSU) who remain symptomatic despite antihistamine treatment Brief titleStudy of efficacy and safety ofXolair® (omalizumab )in Chinese patients with chronic spontaneous urticaria Sponsor and Clinical PhaseNovartis Phase III Investigation typeDrug Study typeInterventional Purpose and rationaleTo evaluate the efficacy of Xolair compared with placebo in patients with refractory CSU receiving concomitant H1 antihistamine therapy as measure d by the ISS and the UAS7 instrument Primary Objective(s)The primary objective is to demonstrate the superiority of omalizumab 300mg or 150 mg administered subcutaneously every 4 weeks in patients with refractory CSU receiving concomitant H1AH therap y with respect to change from baseline in weekl y itch severit y score (ISS7)at Week 12 compared to placebo. Secondary ObjectivesObjective 1:To demonstrate that patients with refractory CSU receiving concomitant H1AH who are treated with omalizumab 300mg or 150mg have a greater reduction from baseline in weekly urticaria activit y score (UAS7 )at Week 12, compared to placebo -treated patients Objective 2: To demonstrate that patients with refractory CSU receiving concomitant H1AH who are treated with omalizumab 300mg or 150mg have a greater reduction from baseline in weekly number of hives score (NHS7 )at Week 12 relative to place bo-treated patients Objective 3: To demonstrate that a greater percentage of patients with refractory CSU receiving concomitant H1AH who are treated with omalizumab 300mg or 150mg have UAS7 ≤ 6 at Week 12 relative to placebo -treated patients Objective 4:To demonstrate that a greater percentage of patients with refractory CSU receiving concomitant H1AH who are treated with omalizumab 300mg or 150mg achieve UAS7 = 0 at Week 12 relative to placebo -treated patients Objective 5: To demonstrate that a great er percentage of patients with"
9,page_9,"Novartis Confidential Page 10 Clinical Trial Protocol (Version 00 ) Protocol No. CIGE025E2305 refractory CSU receiving concomitant H1AH who are treated with omalizumab 300mg or 150mg achieve ISS7 Minimally Important Difference (MID)response at Week 12 relative to placebo -treated patients Objective 6: To demonstrate that patients with refractory CSU receiving concomitant H1AH who are treated with omalizumab 300mg or 150mg have a greater reduction from baseline in Dermatology Life Quality Index (DLQI )at Week 12 relative to placebo -treated patients Objective 7: To e valuate the efficacy of omalizumab compared to placebo in patients with refractory CSU receiving concomitant H1AH therap y with regards to time to ISS7 MI D response b y Week 12 Objective 8: To evaluate the safety of omalizumab compared with placebo in patients with refractory CSU receiving concomitant H1AH therap y with regards to the incidence and severity of adverse events (AE)and serious adverse events (SAE) , vital signs and clinical laboratory evaluation at the end of the stud y Study designRandomi zed, multicenter, double -blind, placebo -controlled, parallel- group study PopulationA total of approximately 600 patients aged 18 to 75 y ears old who have been diagnosed with refractory CSU and who remain symptomatic despite conventional H1AH treatment will be screened to allow 420 patients to be randomized into this study Key Inclusion criteriaDiagnosis of CSU refractory to H1 antihistamines at the time of randomization, as defined by all of the following Age 18 -75 years CSU diagnosis for ≥ 6 months. The presence of itch and hives for ≥ 6 consecutive weeks at any time prior to randomization despite current use of H1AH treatment during this time period. UAS7 score ( range 0-42) ≥ 16 and itch component of UAS7 (range 0to 1)≥ 8 during 7 day s prior to ran domization (Day 1). In-clinic UAS ≥ 4 on at least one of the screening visit days (Day -14, Day -7, or Day 1). Patients must have been on an approved dose of an H1AH for CSU for at least the 3 consecutive days immediatel y prior to the Day -14 screening visit and must have documented current use on the day of the initial screening visit. Key Exclusion criteriaClearly defined underl ying etiology for chronic urticarias other than CSU (main manifestation being ph ysical urticaria). Atopic dermatitis, bullou s pemphigoid, dermatitis herpetiformis, senile"
10,page_10,"Novartis Confidential Page 11 Clinical Trial Protocol (Version 00 ) Protocol No. CIGE025E2305 pruritus or other skin disease associated with itch Urticarial vasculitis, urticaria pigmentosa, erythema multiforme, mastocy tosis, hereditary or acquired angioedema, lymphoma, leukemia, or generalized cancer Study treatmentOmalizumab 150 mg, omalizumab 300 mg and placebo 2:2:1 randomization Efficacy assessmentsweekl y itch severity score (ISS7 )at Week 12 weekl y urticaria activity score (UAS7 )at Week 12 weekl y number of hives score (NHS7 )at Week 12 Percentage of patients who have UAS7 ≤ 6, UAS7 =0, ISS7 MID at Week 12 DLQI Key safety assessmentsSafety of omalizumab compared to placebo with regards to the incidence and severity ofadverse events and serious adverse events, vital signs and clinical laboratory evaluation at the end of the study Data analysisRandomization will be stratified by latent tuberculosis (TB)at baseline (Yes/No ). The primary efficacy variable is change from baseline in weekly itch severit y score ( ISS7 )at Week 12. The daily itch score is the average of the morning and evening itch severit y scores. The baseline ISS7 is the sum of the daily itch severity scores over the 7 days prior to the randomization Day 1 visit, and the ISS7 at Week 12 is the sum of daily itch scores over the 7 days prior to the Week 12 visit. A mixed -effect linear model with repeated measures (MMRM )will be used to obtain the least squares mean (LSM)estimate for each treatment group for change from baseline in ISS7 at Week 12. The MMRM model will include terms of treatment group, week (1 to 12), baseline score, baseline score -by- week interaction, and treatment -by-week interaction as fixed effects. Treatment group and week will be fitted as categorical variables, and baseline score as a continuous covariate. The within -patient correlation will be modeled using the unstructured covariance matrix. The difference in LSM estimates between treatment groups, together with a 95% CI, will be presented. The following secondary efficacy endpoints will be considered and analyzed accordingl y. -Change from baseline in UAS7, NHS7, and overall DLQI at Week 12, respectivel y. For each endpoint, the treatment comparisons of 300mg vs"
11,page_11,"Novartis Confidential Page 12 Clinical Trial Protocol (Version 00 ) Protocol No. CIGE025E2305 placebo and 150mg vs placebo will be made using an MMRM model with similar terms as the primary analysis but the corresponding baseline value as a covariate. -Percentage of patients with UAS7 ≤ 6, UAS7 = 0, and ISS7 MID response at Week 12, respectivel y.For each endpoint, the treatment comparisons of 300 mg vs placebo and 150 mg vs placebo will be performed using a logistic regression model which will be fitted with treatment group as a factor and the corresponding baseline value as a covariate. -Time to ISS7 MID during the randomized- treatment epoch. Treatment comparisons of 300mg vs placebo and 150mg vs placebo will be performed using aCox proportional hazard (PH)model with treatment group as a factor and baseline I SS7 as a covariate. Multiplicity adjustment will be made for testing the primary and secondary hypotheses according to the ty pe I error control plan. Key wordsChronic spontaneous urticaria, ISS7, UAS7, omalizumab, China"
12,page_12,"Novartis Confidential Page 13 Clinical Trial Protocol (Version 00 ) Protocol No. CIGE025E2305 1 Introduction 1.1 Background Urticaria is a heterogeneous group of diseases characterized by hives and/or angioedema (Zuberbier et al 2014) . Chronic spontaneous urticaria (CSU )is defined as the spontaneous occurrence of daily , or almost daily , hives and itching for at least 6 weeks without an obvious cause (Zuberbier et al 2014) . The prevalence of CSU is estimated as 0.5% -1% of the population in Western countries. Women are affected twice as often as men and all age groups can develop CSU; the incidence peak of CSU is between 20 and 40 years (Maurer et al 2011 ). In China, prevalence data for CSU are not available an d an epidemiological survey conducted by China Dermatologist Association is ongoing. According to an epidemiological survey of urticaria conducted by Third Military Medical University in China, CSU accounted for about half of the total urticaria population . Distributions of gender and age among CSU patients were similar to those reported in Western countries (Luo Jie et al 2011) . A recent hospital -based multicenter epidemiological study in the Chinese population found CSU to be the most common subty pe in patients diagnosed with chronic urticaria (61% of all cases ) (Zhong et al 2014 ). Among the proposed etiologies of CSU include those indicating an infectious origin (e.g., Helicobacter pylori ), non- allergic hypersensitivity reactions to foods and drugs (pseudoallergic ),and autoimmunity (Fiebiger et al 1995 ,Tong et al 1997 ,Zweiman et al 1998, Fukuda et al 2004) . In patients suspected of having an autoimmune etio logy of CSU, urticaria symptoms are considered to result from mediator release following the cross -linking of high- affinity immunoglobulin E (IgE)receptors (FcεRI ) on mast cells and basophils. Chronic spontaneous urticaria is associated with immunoglobulin G (IgG) antibodies against IgE receptor α subunit in 35-40% of patients and against IgE in an additional 5-10% (Kaplan and Greaves et al 2009 ). The currently recommended treatment for CSU in the EAACI /GA2LEN/EDF/WAO guidelines (Zuberbier et al 2014) is similar to that in the Chinese Society of Dermatology guideline (CSD 2007) in which non-sedating H1 antihistamines (H1AH )are recommended as first-line treatment. In case of inadequate response to H1AH, switching to another H1AH is recommended. As general practice, use of higher, off-label doses of H1AH is uncommon in China. Other off-label used treatment options in Chinese guideline sinclude leukotriene receptor antagonists or H2 antihistamine therapy . For some CSU patients refractory to H1AH, the guidelines recommend the use of systemic immunosuppressants, such as systemic corticosteroids or cy closporine. However, these drugs are associated with poor tolerabilit y and adverse events in many patients. Further treatment options include psoralen and ultraviolet A radiation, narrow- band ultraviolet phototherap y, dapsone, plasmapheresis, and intravenous immunoglo bulin. Although approximately half or more of CSU patients are considered to be well-controlled by H1AH at approved doses, the treatment options for those who remain symptomatic on treatment with H1AH are quite limited. Some patients benefit from the addit ion of LTRA or H2 antihistamines, systemic corticosteroids or immunosuppressants, but there is insufficient"
13,page_13,"Novartis Confidential Page 14 Clinical Trial Protocol (Version 00 ) Protocol No. CIGE025E2305 evidence for these therapies and many are not approved for CSU. Because chronic spontaneous urticaria has a profound negative impact on patients’ quality of life (Choi WSet al 2016 )there is a high unmet medical need for a new treatments in CSU patients refractory to H1AH. Xolair® (omalizumab )is a humanized anti-IgE recombinant monoclonal antibody approved in 96 countries ,including the US and the EU, totreat allergic asthma. Omalizumab binds to IgE, preventing its binding to FcεRI on the surface of mast cells andbasophils. Reduction of free IgE also leads to reduced cell surface expression of FcεRI. Reduction in free IgE and in cell surface FcεRI limits the extent ofrelease of mediators from mast cells and basophils in the allergic response. The hypotheses for the mechanism of action of omalizumab in CSU patients are (1)lowering free IgE to near undetectable levels leads to down -regulation of IgE receptors, so that IgG autoantibody cannot cross -link the high- affinity receptor (FcεRI ), and (2)the down regulation of FcεRI may be accompanied by an increase in the threshold above which degranulation of mast cells is triggered. The main studies contributing to efficacy data for the CSU indication include a Phase II dose - finding study Q4577g and 3 Phase III placebo -controlled studies (Q4881g, Q4882g, and Q4883g ). Other sources of efficacy data include an initial placebo -controlled study (ADE05 ) conducted locall y in Germany prior to the Phase III program in CSU and small investigator - initiated placebo -controlled pilot study(Kaplan et al 2008) . The studies used for pooled efficacy analysis were Q4881g and Q4882g. Efficacy was assessed using well -established and validated endpoints, based on the Urticaria Activity Score (UAS ). The Phase III studies were designed to select adult and adolescent patients (12 years and older )with severe, significant impairment of quality of life and refractoriness to current standard therapy . The pivotal efficacy studies, Q4881g and Q4882g, used doses of 75 mg, 150 mg and 300 mg administered every 4 weeks during 24 weeks and 12 weeks, respectively . A consistent dose response was observed across the primary and secondary endpoints. On the basis of the efficacy observed in the Phase III program, omalizumab 300 mg and 150 mg, given subcutaneously every 4 weeks , are recommended doses for the treatment of CSU. The safet y profile in CSU is consistent with that previously reported for the allergic asthma indication. Four studies ,one Phase II (4577g )and three Phase III studies (Q4881g ), (Q4882g ), and (Q4883g ), with a total of 1,068 patients, contributed data to the integrated evaluation of safet y of omalizumab in CSU, including 802 patients who received one or more doses of omalizumab. There were no deaths or major organ toxicity and a similar incidence of adverse events and severe adverse events among the treatment groups was apparent, with no age- specific safet y concerns. Omalizumab is now approved for the treatment of CSU in 53 countries worldwide including the US, the EU (counted as one), Canada, and Australia (as of April 2016). In the EU, only the 300 mg dose of omalizumab is approved whereas 300 mg and 150 mg are approved in most other regions. 1.2 Purpose The purpose of this study is to demonstrate the efficacy and safety of omalizumab, compared with placebo, as an add -on to H1AH therapy in adult patients suffering from CSU who remain"
14,page_14,"Novartis Confidential Page 15 Clinical Trial Protocol (Version 00 ) Protocol No. CIGE025E2305 symptomatic despite H1AH therap y. The results of this study will support registration of omalizumab for adult patients suffering from CSU in China, and potentially in other countrie s. 2 Study objectives and endpoints 2.1 Objectives and related endpoints Table 2 -1 Objectives and related endpoints Objective Endpoint Analysis Primary To demonstrate the superiority of omalizum ab 300mg or 150mg administered subcutaneously every 4 weeks in patients with refractory CSU receiving concomitant H1AH therapy with respect to change from baseline in weekly itch severity score (ISS7 )at Week 12,compared to placeboThe primary efficacy variable is defined as the change from baseline of the ISS7 score after 12 weeks of treatmentSection 9.4 Secondary To demonstrate that patients with refractory CSU receiving concomitant H1AH who are treated with omalizum ab 300 mg or 150mg have a greater reduction from baseline in weekly urticaria activity score (UAS7 )at Week 12, compared to placebo - treated patients To demonstrate that patients with refractory CSU receiving concomitant H1AH who are treated with omalizum ab 300 mg or 150mg have a greater reduction from baseline in weekly number of hives score (NHS7 )at Week 12 relative to placebo -treated patients To demonstrate that a greater percentage of patients with refractory CSU receiving concomitant H1AH who are treated with omalizumab 300mg or 150mg have UAS7 ≤6 at Week 12 relative to placebo -treated patients To demonstrate that a greater percentage of patients with refractory CSU receiving concomitant H1AH who are treated with omalizumab 300mg or 150mg achieve UAS7 =0 at Week 12 relative to placebo - treated patients To demonstrate that a greater percentage of patients with refractory CSU receiving concomitant H1AH who are treated with omalizumab 300mg or 150mg achieve ISS7 Minimally Important Difference (MID) response at Week 12 relative to placebo -treated patients To demonstrate that patients with refract ory CSU receiving concomitant H1AH who are treated with omalizum ab 300mg or 150mg have a greater Variables and timepoint: UAS7 Change from Baseline of UAS7 score after 12 weeks of trea tment Percentage of patients with UAS7 ≤6 at Week 12 Percentage of patients with UAS7=0 at Week 12 NHS7 Change from Baseline of NHS7 score after 12 weeks of treatment ISS7 Percentage of patients with ISS7 MID at week 12 Time to ISS7 MID response by W eek 12 DLQI Change from Baseline of DLQI score after 12 weeks of treatment SafetySection 9.5"
15,page_15,"Novartis Confidential Page 16 Clinical Trial Protocol (Version 00 ) Protocol No. CIGE025E2305 Objective Endpoint Analysis reduction from baseline in Dermatology Life Quality Index ( DLQI )at Week 12 relative to placebo -treated patients To evaluate the efficacy of omalizum ab compa red with placebo in patients with refractory CSU receiving concomitant H1AH therapy with regards to time to ISS7 MID response by W eek 12 To evaluate the safety of omalizumab compared with placebo in patients with refractory CSU receiving concomitant H1AH therapy with regards to the incidence and severity of adverse events and serious adverse events, vital signs and clinical laborator y evaluation at the end of the studyPercentage of patients with AE, with SAE, and who discontinue due to an AE Exposure adjusted AE event rates Percentage of patients with a clinically notable abnormality in Lab, ECG, and vital signs Change from baseline in Lab, ECG, and vital signs"
16,page_16,"Novartis Confidential Page 17 Clinical Trial Protocol (Version 00 ) Protocol No. CIGE025E2305 3 Investigational plan 3.1 Stud y design The study is a Phase III, multicenter, randomized, double -blind, placebo -controlled, parallel - group study to evaluate the efficacy and safet y of omalizumab administered subcutaneousl y as an add -on therap y for the treatment of patients aged 18-75 years with the diagnosis of refractory CSU and who remain symptomatic despite approved -dosed H1AH treatment. Patients will be randomized into three treatment arms (omalizumab 300 mg s.c., omalizumab 150 mg s.c., and placebo )in a 2:2:1 ratio, stratified by latent TB status at baseline. Approximately 420 patients will be enrolled at approximately 30 study sites. The study will consist of three distinct epochs over 24weeks, as outlined below (see also Figure 3 - 1). Screening epoch: Day -28to Day -1 Randomized -treatment epoch: Day 1 to Week 12 Post-treatment follow- up epoch: Week 12 to Week 20"
17,page_17,"Novartis Confidential Page 18 Clinical Trial Protocol (Version 00 ) Protocol No. CIGE025E2305 Figure 3-1 Study design Eligible patients will be required to visit at Day -28~-14 and Day -7 during the 2-4 week screening epoch. Onlyin casesof outstanding laboratory results will an extended screening epoch be permitted. For the duration of t he screening epoch, patients are recommended to stay on a stable CSU H1AH treatment. In addition, for patients requiring treatment for latent TB, screening epoch will be extended in order to allow for a 4-Week treatment period prior to randomization. On Day 1, eligible patients will be randoml y assigned (in a 2:2:1 ratio with an Interactive Response Technology [IRT] )to receive omalizumab (150 mg or 300mg)or placebo by subcutaneous injection every 4 w eeks (on Day 1, Week 4, and Week 8)during the 12-week double -blind randomized- treatment epoch. Approximately 168 patients will be randomized to the omalizumab 150mg, approximately 168 patients to omalizumab 300mg and approximately 84 patients will be randomized to receive placebo. For the duration of the randomized- treatment epoch, patients are recommended to stay on the same CSU H1AH treatment that they were using during the pre-randomization period. The last dose of study drug during the randomized -treatment epoch will be administered at Week 8 study visit. The primary endpoint will be assessed at Week 12. After the completion of the 12-week randomized- treatment epoch, all patients will enter an 8-week post-treatment follow -up epoch to allow for further characterization of omalizumab and collection of additional efficacy and safety data. All these evaluations will"
18,page_18,"Novartis Confidential Page 19 Clinical Trial Protocol (Version 00 ) Protocol No. CIGE025E2305 also be done for those who withdraw from the study within 12 weeks of randomization. During the post -treatment follow- up epoch, patients would be allowed to add one more H1AH therap y to their treatment regimen for CSU. This is expected to help limit patient dropout and ensure that patients return for safety evaluations during the post -treatment follow- up epoch. For the duration of the study , patients will visit the study center at 4-week intervals. No study drug treatment will be given during the post-treatment follow -up epoch. The blind will be maintained for the full 20 weeks of the study (after randomization ). For the duration of the study , all patients will be provided di phenh ydramine (25mg)tablets as rescue medication ( see Section 5.5.6 )for additional itch relief on an as -needed basis (up to a maximum of three doses in 24 hours or less, based on local regulations ). No other medication for itch relief will be allowed during the screening and treatment phases of the study . 3.2 Rationale for study design This is a randomized, double -blind, parallel -group, placebo -controlled study to demonstrate the efficacy and safety of omali zumab in Chinese patients with CSU who remain s ymptomatic despite H1AH therap y compared with placebo. The study design is aligned with previous pivotal efficacy studies Q4881g and Q4882g. Efficacy is determined using the primar y endpoint of change from bas eline in the weekl y itch severit y score at Week 12 because itching is the sy mptom of greatest concern to patients, with the greatest impact on their quality of life (Mathias et al 2010) . As CSU is both a disease of hives and intense itch, it is appropriate to evaluate clinical response assessing hives, as well as using a composite endpoint, UAS, which incorporates assessment of both symptoms. Therefore the UAS will be incorporated as a secondary endpoint. The validity and reliability of UAS in CSU has been established in previous studies (Mylnek et al 2008 ,Mathias et al 2012 ). The selection of Week 12 as the time point for primary efficacy assessment is consistent with previous studies conducted with omalizumab in CSU and is supported by the finding that response to omalizumab plateaued after 12 weeks in these studies. The reason for including only patients who are refractory to approved doses of H1AH therapy is that H1AH drugs are the approved first line therapy for CSU (Zuberbier et al 2009 ,Hide and Hiragun 2012) , and the unmet medical need in CSU is highest in patients refractory to these drugs. Omalizumab will be used as an add -on therap y on top of H1AH treatment in this study . 3.3 Rationale for dose/regimen, route of administration and duration of treatment The doses for this study are selected based on the results of the Phase III studies Q4881g and Q4882g that tested omalizumab doses of 75 mg, 150 mg, 300 mg and placebo. The doses for these Phase III studies were selected based on the results from the Phase II dose finding study Q4577g that tested a broad array of omalizumab doses (75, 300, and 600 mg)as a single subcutaneous injecti on in patients with CSU refractory to H1AH. Based on the results from these studies, 300 mg and 150 mg doses are the recommended doses and have been approved in most regions worldwide. Efficacy and safet y with these doses is expected to be similar in the C hinese population. The rationale for the dose/regimen chosen for this study is summarized as follows:"
19,page_19,"Novartis Confidential Page 20 Clinical Trial Protocol (Version 00 ) Protocol No. CIGE025E2305 In the phase II study Q4577g, the 300 mg and 600 mg omalizumab dose groups both demonstrated efficacy superior to the placebo group, but there was no additional benefit observed for the 600 mg omalizumab group compared with the 300 mg omalizumab group. In exposure -response anal ysis, exposure levels at 300 mg appeared to approach the plateau of the exposure –response curve. In studies Q4881g and Q4882g, on th e primary endpoint (change from baseline to Week 12 in weekl y itch severit y score ), omalizumab 150 mg and 300 mg given every 4 w eeks demonstrated consistent and statistically significant treatment effects relative to placebo. The 75 mg dose did not show a consistent effect on the primary endpoint and most secondar y endpoints. The safet y profile for omalizumab in CSU is consistent with the profile previously reported for the allergic asthma indication. The safety profile was similar for the 150 mgand 300 mg doses in studies Q4881g and Q4882g, and consistent with the profile for the 300 mg dose used in the safet y stud y Q4883g. Based on exposure -response analy sis of omalizumab in CSU, there was a dose response in efficacy (itch improvement and percent complete UAS7 responders )across the dose range tested (75 mg to 300 mg every 4 w eeks), and no clear impact of body weight, body mass index (BMI)and baseline IgE on efficacy within each dose level. This result was again confirmed in phase III studies. Flat dosing (ie., without adjustment for baseline body weight and/or IgE level )is therefore supported. The 4 weeks dosing interval is selected because in the phase II study Q4577g maximum effect was observed 4 weeks post-dose. The appropriateness of the 4 week dosing interval was confirmed by PK/PD itch and hives time course modeling using the Phase IIIstudy data. An interval of 4 weeks is considered to minimize breakthrough CSU symptoms while avoiding accumulation resultin g from dosing omalizumab more frequently than necessary . There was no clinically significant difference found in PK and PD of omalizumab between Chinese and Caucasian populations. Thus, Chinese subjects should respond similarly to Caucasians when omalizuma b is given with the same dose/regimen as used in the previous studies (A2102, A2204 and A2206). Flat dosing Based on these findings, it is considered appropriate to select 150 mg and 300 mg doses for E2305 study . This study would attempt to further charact erize the dose response profile for omalizumab in CSU with the objective of identify ing the optimal dose in Chinese patients. The rationale for a treatment (study drug administration )period of 12 weeks isdescribed below: Treatment with omalizumab results in a rapid reduction of CSU symptoms .The global phase III studies demonstrated that the time to achieve the minimally important difference response (decrease in UAS7 ≥ 5) was 1 to 2 weeks after the start of treatment. The global phase III studies showed no clear differences in therapeutic efficacy after 12 and 24 weeks of treatment, indicating that efficacy beyond Week 12 can be extrapolated from the Week 12 response."
20,page_20,"Novartis Confidential Page 21 Clinical Trial Protocol (Version 00 ) Protocol No. CIGE025E2305 The rationale for establishing an 8-week follow -up epoch after the end of the treatment epoch is that this is deemed sufficient to provide safety data and assessment of anti-therapeutic antibodies ( ATA ). 3.4 Rationale for choice of comparator In this trial ,omalizumab is investigated as add -on therapy to H1AHs and compared to placebo to determine the efficacy and safet y of omalizumab as add -on therapy . During the 12 weeks of the treatment epoch, placebo will be given to the 150 mg group (150 mg omalizumab a nd 150 mg placebo )and placebo group (150 mg placebo x 2 ) (Table 3 -1). All patients must take study -defined H1AH medications at approved doses during the screening, treatment, and post-treatment follow -up epochs, which is typical for placebo - controlled trials where an add-on therap y is studied for a disease with apre-existing standard of care. Patients should remain on a stable H1AH treatment regimen throughout the study . Diphenhy dramine will be allowed as rescue medication (seeSection 5.5.6 ).Diphenh ydramine 25 mg will be provided and used on an as -needed basis ( up to a maximum of three doses of 25 mg in 24 hours according to the Chinese label )during the screening, randomized treatment, and post-treatment follow -up epochs. Patients will be permitted to add up to one additional H1AH therapy after the primary endpoint has been assessed at Week 12to reduce patient dropout during the post -treatment follow -up epoch. The use of placebo arm in this trial is deemed mandatory to demonstrate the efficacy and safet y of Xolair in Chinese patients suffering from CSU. The 2:2:1 randomization serves to limit the proportion of patient that will receive placebo during the study to 20% of patients. Moreover, patients in the placebo arm will receive standard of care treatment with H1AH therap y throughout the study and will be allowed to receive rescue medication. Table 3-1 Number of study drug administrations at Day 1 and at Weeks 4 and 8 Treatment Arm Omalizumab 300 mg Omalizumab 150 mg Placebo Active drug (omalizumab 150 mg/vial) 2 1 0 Placebo (150mg/vial) 0 1 2 3.5 Purpose and timing of interim analy ses/design adaptations Interim anal yses or design adaptation arecurrently not planned. 3.6 Risks and benefits Based on results from multiple global studies, omalizumab treatment has a positive benefit - risk ratio for severe, refract ory CSU patients ateither of the proposed doses. Patients treated with omalizumab can achieve a clinicall y relevant reduction in persistent and debilitating symptoms associated with the disease, while maintaining a safety profile consistent with the known safet y profile in allergic asthma."
21,page_21,"Novartis Confidential Page 22 Clinical Trial Protocol (Version 00 ) Protocol No. CIGE025E2305 Omalizumab has been approved for allergic asthma in 96 countries worldwide based onthe positive benefit -risk ratio from the submitted clinical trials. Omalizumab was approved for the treatment of CSU in the EU and in th e US in 2014. As of May 2016, omalizumab is approved for CSU in 83 countries worldwide including USA, EU, Switzerland, Canada, and Australia. For CSU, significant and consistent results were apparent across all the Phase III studies. On thebasis of the efficacy observed in the phase III program, omalizumab doses of 300 mg and 150 mg administered every 4 w eeks, result in a fast onset of treatment effect (within 1-2 weeks )for the majorit y of patients, with significant improvement relative to placebo being demonstrated for itch, hives and associated CSU symptoms. There were no reported deaths, and few serious adverse events. Omalizumab was well-tolerated in all the clinical studies and the observed adverse events were broadl y similar across each treatment g roup. Overall no new safet y concerns were raised when these data are compared with the adverse reactions (AR) listed in the current prescribing information for omalizumab. The safet y profile for omalizumab in CSU is consistent with the profile previously reported for the allergic asthma indication. There were no deaths or major organ toxicity in any SOC and a similar incidence of AEs and SAEs among the treatment groups with no age specific safet y concerns. However, small imbalances were observed in some SOC s, as listed below with the event (s) that contributed to the imbalance bracketed: General disorders and administration site disorders (injection site reactions), Infections and infestations ( upper respiratory tract infection, urinary tract infection ), Musc uloskeletal and connective tissue disorders (arthralgia ), Nervous system disorders (headache ), and Respiratory , thoracic and mediastinal disorders (coughing, bronchospasm )were reported more frequently in the omalizumab treatment groups than in the placebo group. The preferred terms noted above are not necessarily the same events identified as advers e reactions (ARs). These were identified from candidate events where the incidence on any omalizumab dose was ≥2% higher than in the placebo group. The events noted as ARs in the pooled CSU safet y database are nasophary ngitis, viral upper respiratory tract infection, sinusitis, arthralgia, and headache. Apart from a few specific preferred terms, the other relativel y small imbalances observed were in line with the well characterized safet y profile of omalizumab in the severe allergic asthma indication, and with events listed in the adverse reaction (AR)table in the SmPC. Among the more commonly reported AEs, headache was the only notable event that was reported more frequently relative to placebo in the omalizumab 150 mg and 300 mg dose groups. Most events seen were mild to moderate in severity , and no meaningful difference between treatment groups was seen for severe events during the treatment periods. The perce ntage of patients with AEs suspected by the investigator to be related to study drug was slightly higher in the omalizumab groups (range 7.5% to 9.2%) compared to placebo (5.8%). The small imbalance with omalizumab 300 mg was partly due to preferred terms headache, and injection site reactions. The incidence of SAEs, discontinuations from study due to an AE, and withdrawals from treatment were similar or lower with omalizumab treatment compared to placebo, so do not present an incremental risk to patients."
22,page_22,"Novartis Confidential Page 23 Clinical Trial Protocol (Version 00 ) Protocol No. CIGE025E2305 Among a range of AEs of special interest examined, hypersensitivity , injection site reaction, and hematopoietic cy topenia were reported at higher rates with omalizumab 300 mg treatment, and were consistent with previous clinical experience with omalizumab. There were no clinically relevant differences observed between treatment groups for hematology or vital signs, and no meaningful differences between treatment groups were observed for new abnormalities. During the follow -up period, imbalances were seen in the omalizumab groups compared to placebo in the SOCs of infections and infestations (150 mg and 300 mg omalizumab groups ), and skin and subcutaneous tissue disorders (all omalizumab groups ). An increase in skin and subcutaneous events was likely due to the re-emergence of symptoms present at baseline, while the imbalance in infections was similar or lower to the difference seen under active treatment, and showed no clear dose -dependence. The safet y profi le is subject to regular review (PSUR 21, Feb 2016) and updates to the existing risk management plan omalizumab for allergic asthma and CSU. No new risks were identified in the latest version of the risk management plan ( Core RMP 11, April 2016 ), Other treatment alternatives to omalizumab for patients that have failed the standard treatment paradigm of H1 antihistamines at approved, or multiple doses include immunosuppressive agents such as cyclosporine, or repeated exposure to oral glucocorticoids. Ther e are significant potential adverse effects associated with both of these alternatives and due to safet y concerns can onl y be administered over short periods of time. Therefore, the benefit of treatment with omalizumab is that it could improve itch, hives and associated CSU symptoms in a patient population that is refractory to current standard of care. The risks for patients participating in this study include the potential for known safet y issues associated with omalizumab, which includes anaphy laxis, with an estimated incidence of at least 0.2%, as well as the potential for additional risks outlined in the Investigator’s Brochure. Based on the proposed mechanism of action of omalizumab, there is no clear scientific rationale to suspect a decrease in immun ity to tuberculosis (TB)associated with its use, nor clinical data suggesting relapse or worsening of TB in patients treated with omalizumab. Nevertheless, given the high incidence of TB in China that is up to 20 -fold as high as those in EU and US (WHO 2015 ), TB screening will be performed in the study . Patients screened with latent TB will need to receive tuberculosis prophy laxis for at least 4 weeks prior to study drugs (for details, see Section 6.2.1 ). 4 Population A total of approximately 600 patients from a pproximately 30sites in China mainland, aged 18 to 75 years old who have been diagnosed with refractory CSU and who remain symptomatic despite conventional H1AH treatment will be screened to allow 420 patients to be randomized into this study . This accounts for approximately 30% screening failures. If the maximum earl y discontinuation rate of 10% is assumed for this study , then approximately 375 subjects are expected to be able to complete the 12 -week randomized- treatment epoch with primary efficacy data available at the endpoint."
23,page_23,"Novartis Confidential Page 24 Clinical Trial Protocol (Version 00 ) Protocol No. CIGE025E2305 4.1 Inclusion criteria Patients/subjects eligible for inclusion in this study must fulfill all of the following criteria: 1. Written informed consent must be obtained before any assessment is performed. 2. Aged 18 -75 years. 3. Diagnosis of CSU refractory to H1AH at the time of randomization, as defined by all of the following: CSU diagnosis for ≥ 6 months. The presence of itch and hives for ≥ 6 consecutive weeks at any time prior to randomization despite current use of H1AH treatment during this time period. UAS7 score (range 0-42) ≥ 16 and itch component of UAS7 (range 0-21)≥ 8 during 7 days prior to randomization (Day 1). In-clinic UAS ≥ 4 on at least one of the screening visit day s (Day -14, Day -7, or Day 1). Patients must have been on an approved dose of an H1AH for CSU for at least the 3 consecutive days immediately prior to the Day -14 screening visit and must have documented current use on the day of the initial screening visit. 4. Willing and able to complete a dail y symptom eDiary for the duration of the study . 5. Patients must not have had any missing eDiary entries in the 7 day s prior to randomization . 4.2 Exclusion criteria Patients fulfilling any of the following criteria are not eligible for inclusion in this study . No additional exclusions may be applied by the investigator in order to ensure that the study population will be representative of all eligible patients/subject s. 1. Clearly defined underl ying etiology for chronic urticarias other than CSU. This includes the following: Acute, solar, cholinergic, heat, cold, aquagenic, delay ed pressure or contact urticarias; Any of the following diseases, which may have sy mptoms of u rticaria and/or angioedema: urticarial vasculitis, urticaria pigmentosa, erythema multiforme, mastocytosis, hereditary or acquired angioedema, ly mphoma, leukemia, or generalized cancer 2. Patients with a stool examination positive for ova or parasites (at screening ) (patients should be cautioned and instructed to apply appropriate hygienic measurements when travelling to areas where helminthic infections are endemic ). 3. Any skin disease other than CSU with chronic itching that could confound the results of the study (e.g., atopic dermatitis, bullous pemphigoid, dermatitis herpetiformis, or senile pruritus ). 4. Previous treatment with omalizumab. 5. Contraindications to diphenhy dramine:"
24,page_24,"Novartis Confidential Page 25 Clinical Trial Protocol (Version 00 ) Protocol No. CIGE025E2305 Hypersensitivity to diphenhy dramine or other antihistaminic agents; acute bronchi al asthma; acute angle -closure glaucoma; pheochromocy toma; hyperplasia of the prostate gland with formation of residual urine; epilepsy ; hypokalemia; hypomagnesemia; brady cardia; a congenital long QT syndrome or other clinically significant cardiac disorde rs (especially coronary heart disease, disturbances in conduction, arrhy thmias ); the simultaneous application of drugs which prolong the QT interval (e.g., antiarrhythmic drugs Class IA or III, antibiotics, cisapride, malaria drugs, neuroleptic drugs )or lead to hypokalemia (e.g., certain diuretic drugs ); the simultaneous application of monoamine oxidase inhibitors; the simultaneous uptake of alcohol . 6. History of anaph ylactic shock . 7. Patients with platelet count ≤ 100,000 / μL at Visit 1 . 8. Patients who are sucrose-intolerant (e.g., the glucose -galactose malabsorption syndrome, fructose intolerance or sucrose- isomaltase deficiency ). 9. Presence of clinically significant cardiovascular, neurological, psychiatric, metabolic, hepatic, or other pathological conditions that could interfere with the interpretation of the study results and or compromise the safet y of the patients . 10. Medical examination or laboratory findings that suggest the possibility of decompensation of co-existing conditions for the duration of the study . Any items that are cause for uncertaint y will be reviewed with the investigator. 11. Inability to compl y with study and follow -up procedures . 12. History or evidence of ongoing alcohol or drug abuse, within the last 6 months prior to randomization . 13. Patients who have been previously randomized into this study . 14. Use of other investigational drugs within 5 half-lives of enrollment, or within 30 daysuntil the expected pharmacodynamic effect has returned to baseline, whichever is longer. 15. History of hypersensitivity toany of the study drugs or its excipients or to drugs of similar chemical classes. 16. History or current diagnosis of ECG abnormalities indicating significant risk of safety for patients/subjects participating in the stud y such as: Concomitant clinically significant cardiac arrhy thmias, e.g., sustained ventricular tachycardia, and clinically significant second or third degree AV block without a pacemaker History of familial long QT sy ndrome or known family history of Torsades de Pointes 17. Patients taking medications prohibited by the protocol (see Section 5.5.8 , Table 5 -1) 18. History of malignancy of any organ system regardless of whether there is evidence of local recurrence or metastases (except basal cell carcinoma, actinic keratosis, or Bowen’s disease [squamous carcinoma in situ] that have been treated with no evidence of recurrence in the past 12 weeks; carcinoma in situof the cervix or non- invasive malignant colon polyps that have been removed treated or untreated, within the past 5 y ears) 19. Pregnant or nursing (lactating )women 20. Women of child -bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using basic methods of contraception during dosing of investigational drug. Basic contraception methods include:"
25,page_25,"Novartis Confidential Page 26 Clinical Trial Protocol (Version 00 ) Protocol No. CIGE025E2305 Total abstinence (when this is in line with the preferred and usual lifesty le of the subject ). Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception Female sterilization (have had surgical bilateral oophorectom y with or without hysterectomy), total hysterectom y or tubal ligation at least six weeks before taking investigational drug. In case of oophorectom y alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment Male sterilization (at least 6 months prior to screening ).For female subjects on the study , the vasectomized male partner should be the sole partner for that subject Barrier methods of contraception: Condom or Occlusive cap (diaphragm or cervical/vault caps). Use of oral, (estrogen and progesterone ), injected or implanted hormonal methods of contraception or other forms of hormonal contraception that have comparable efficacy (failure rate< 1%), for example hormone vaginal ring or transdermal hormone contraception or placement of an intrauterine device ( IUD)or intrauterine sy stem (IUS). In case of use of oral contraception women should have been stable on the same pill for a minimum of 3 months before taking investigational drug. Women are considered post -menopausal and not of child bearing potential if they have had 12 months of natural (spontaneous ) amenorrhea with an appropriate clinical profile (e.g., age appropriate, history of vasomotor symptoms )or have had surgical bilateral oophorectomy (with or without hysterectomy ), total hysterectomy or tubal ligation at least six weeks ago. In the case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment is she considered not of child bearing potential. 21. Patients with evidence of latent TB infect ion, as defined by a positive QuantiFERON TBGold Test (QFT ), who are unwilling to be treated with TB treatment according to local country guidelines, or cannot, demonstrate documented compliance with prior treatment of latent TB infection according to local country guidelines. Patients with a positive QFT are required to have a chest X-ray, computerized tomography (CT scan), or MRI, obtained within 12 weeks prior to baseline, to evaluate for the potential for prior or current active TB by a q ualified physician. Patients with evidence of prior or current active TB cannot participate further in the trial. 5 Treatment 5.1 Stud y treatment 5.1.1 Investigational and control drugs Name: Omalizumab ( IGE025 ) Formulation: Ly ophilized powder for solution for injection Appearance: White cake, reconstituted solution: colorless to pale yellow and clear to slightly opalescent"
26,page_26,"Novartis Confidential Page 27 Clinical Trial Protocol (Version 00 ) Protocol No. CIGE025E2305 Unit dose: 150 mg/vial Packaging: Glass vial The appearance of omalizumab vial differs from that of placebo vial, and the viscosity of omalizumab differs from that of placebo. Omalizumab matching placebo provided in 5ml glass vial. 5.1.2 Additional treatment Except for the concurrent use of H1AH and diphenhy dramine as rescue medication (see Section 5.5.6 ), no additional treatment beyond investigational treatment is requested for this trial. The long -acting non -sedating H1AH agents are allowed during the study . Dosage and administration should follow local regulations 5.2 Treatment arms Patients will be randomized to one of the following three treatment arms in a ratio of 2:2:1. Omalizumab 300mg arm will receive a dose of omalizumab 300mg s.c. which consists of two injections of omalizumab 150 mg vials every 4 weeks. Omalizumab 150mg arm will receive a dose of omalizumab 150 m g s.c. which consists of one injection of omalizumab 150 mg vial and one injection of placebo 150mg vial every 4 weeks. Placebo arm will receive placebo s.c. which consists of two injections of placebo 150 mgvials every 4 weeks. A detailed schedule of administration is described in Section 6 . As this is a double -blind study , the dispensing and administration of the study treatments will be performed by suitabl y qualified personnel who are otherwise notinvolved in study conduct. Further details are provided in Section 5.3 ,Section 5.4 and Section 5.5 . 5.3 Treatment assignment and randomization At Visit “101 ,” all eligible patients will be randomized via Interactive Response Technology (IRT)to one of the treatment arms. The unbli nded authorized staff will contact IRT at Visit 101 after confirming that the patient fulfills all the inclusion/exclusion criteria. Also, the unblinded authorized staff will contact the IRT at Visits 102 and 103. The blinded staffs must not contact the IRT at the above visits. The IRT will assign a randomi zation number to the patient, which will be used to link the patient to a treatment arm and will specify a unique medication number for the first package of study drug to be dispensed to the patient. The randomization number will not be communicated to anyof the site staff. The randomization numbers will be generated using the following procedure to ensure that treatment assignment is unbiased and concealed from patients/subjects and investigator staff. A patient randomization list will be produced by the IRT provider using a validated system that automates the random assignment of patient numbers to randomization numbers. These randomization numbers are linked to the different treatment arms, which in turn are linked to medication numbers. A separate medic ation list will be produced by or under the"
27,page_27,"Novartis Confidential Page 28 Clinical Trial Protocol (Version 00 ) Protocol No. CIGE025E2305 responsibility of Novartis Drug Suppl y Management using a validated system that automates the random assignment of medication numbers to packs containing the investigational drug (s). Randomization will be strati fied b y latent TB at baseline (Yes/No ). The randomization scheme for patients/subjects will be reviewed and approved by a member of the Randomization Group. 5.4 Treatment blinding All data up to final database lock will be collected with the Novartis clinical trial team, investigator / site personnel evaluating subjects, and subjects blinded to treatment allocation. The Novartis clinical team will be blinded during the study until the final database is locked, and all site personnel including the assessor performing the study assessments, will also remain blinded to individual treatment allocation until after final database lock. This excludes the unblinded pharmacist and unblinded health care professional who will dispense and / or administer the study drug and not be involved in the study assessments. An unbli nded pharmacist and an unblinded health care professional are required because they will be able to determine whether the study drug is active or not from the appearance of vial and the viscosit y of the d rug. Blinding will be maintained using the following methods: 1.Randomization data will be kept strictly confidential until the time of unblinding, and will not be accessible by anyone else involved in the study with the following exceptions: Drug Supply Management (DSM ), Drug Safet y & Epidemiology (DS&E )and specific vendors whose role in trial conduct requires their unblinding Unblinded pharmacist and unblinded health care professional at each site Unblinded monitor 2. P lacebo and active treatment will be dispensed by an unblinded pharmacist (or other authorized unblinded staff)who is independent of those involved in the assessment of study subjects. In addition, the unblinded pharmacist (or other authorized unblinded staff)will store study medication and keep medication records containing unblinded information in a secure area where blinded staff would not have access. 3.Study treatments will be administered by an unblinded suitably authorized individual (health care professional) who is not responsible for any aspect of subject assessment or follow-up. 4.The procedural details relating to treatment blinding and unblinded drug administration will be described in the Pharmacist Manual which will be provided separately . Inthe event that the packaging of a study treatment has a broken seal, this information will be documented in the IRT, along with a reason (if applicable )and the medication number so that the vial will not be available to dispense to another subject."
28,page_28,"Novartis Confidential Page 29 Clinical Trial Protocol (Version 00 ) Protocol No. CIGE025E2305 Unblinding will only occur in the case of subject emergencies (seeSection 5.5.9 )and at the conclusion of the study . The appropriate personnel from the study site and Novartis will assess whether the study treatment should be discontinued for any subject whose treatment code has been broken inadvertentl y for any reason. Study treatment must be discontinued after emergency unblinding. 5.5 Treating the patient Sponsor qualified medical personnel will be readily available to advise on trial related medical questions or problems. 5.5.1 Patient number ing, Each patient is uniquely identified by a Subject Number which is composed by the site number assigned by Novartis and a sequential number assigned by the investigator. Once assigned to a patient, the Subject Number will not be reused. Upon signing the informed consent form, the patient is assigned the next sequential number by the investigator. The investigator or his/her staff will contact the IRT and provide the requested identify ing information for the patient to register them into the IRT. The site must select the CRF book with a matching Subject Number from the EDC sy stem to enter data. If the patient fails to be treated for any reason, the IRT must be notified within 2 day s that the patient was not treated. The reason for not being treated will be entered on the Screening epoch Study Disposition CRF. 5.5.2 Dispensing the study drug Each stud y site will be supplied with open -label study drug. The study drug packaging has a 2-part label. A unique medication number is printed on each part of this label which corresponds to one of the omalizumab 150mg or placebo . Unblinded site personnel will identify the investigational treatment package (s)todispense to the patient by matching medication numbers obtained from IRT. Immediatel ybefore dispensing the package to the patient, unblinded site personnel will detach the outer part of the label from the packaging and affix it to the Investigational Product accountability log source document (Drug Label Form ) for that patient’s unique subject number. The stud y drugs will be dispensed by the unblinded pharmacist (or other unblinded authorized site personnel )appointed at the study site. 5.5.3 Handling of study and additional treatment 5.5.3.1 Handling of study treatment Study treatment must be received by a designated person at the study site, handled and stored safel y and properl y, and kept in a secured location to which only the investigator and"
29,page_29,"Novartis Confidential Page 30 Clinical Trial Protocol (Version 00 ) Protocol No. CIGE025E2305 designees have access. Upon receipt, all study treatment must be stored according to the instructions specified on the labels. The study drugs should be received by unblinded staff only. The blinded team should not have access to storage location or should not be involved in receipt of IP.Clinical supplies are to be dispensed only in accordance with the protocol. Technical complai nts are to be reported to the respective Novartis CPO Quality Assurance. Medication labels will include Chinese and comply with the legal requirements of China . They will include storage conditions for the study treatment but no information about the patient except for the medication number . The investigator must maintain an accurate record of the shipment and dispensing of study treatment in a drug accountabili ty log. Monitoring of drug accountability will be performed by monitors during site visits or remotel y and at the completion of the trial At the conclusion of the study , and as appropriate during the course of the study , the investigator will return all unused study treatment, packaging, drug labels, and a copy of the completed drug accountability log to the Novartis monitor or to the Novartis address provided in the investigator folder at each site. 5.5.3.2 Handling of additional treatment The background treatme nt H1AH will be provided by the study site.For the use of H1AH please refer to Section 5.5.7 . 5.5.4 Instructions for prescribing and taking study treatment Active or placebo omalizumab will be administered bysubcutaneous injection. The first administration of drug will take place at Visit 101 once all eligibility criteria have been confirmed and all other assessments performed. The lyophilized product takes 15-20 minutes to dissolve. The fully reconstituted product will appear clear or slightl y opalescent and may have a few small bubbles or foam around the edge of the vial. Detailed instructions on how to reconstitute omalizumab vials can be found in the separate Pharmacist Manual. Reconstituted omalizumab vials should be protected from direct sunlight. Administration Study medication will be administered by an unblinded suitably authorized individual (qualified health care professional )who is not responsible for any aspect of subject assessment or follow -up. This individual will be identified at site as the “independent study drug administrator”. The independent study drug administrator will administer the study treatment to the corresponding subject by s.c. injection during the study visit without engaging in any unnecessary interactions that may have the potential to unblind the subject or any of the site study personnel. Study drug is administered to the patient using a disposable 25-gauge needle and a disposable plastic tuberculin -type syringe. The injecti ons are administered in the deltoid region on the right arm and/or left arm, avoiding urticarial lesions. Alternatively , the injections can be administered in the thigh if reasons preclude administration in the deltoid region. The injections are administer ed subcutaneously after aspiration of the plunger of the syringe. If"
30,page_30,"Novartis Confidential Page 31 Clinical Trial Protocol (Version 00 ) Protocol No. CIGE025E2305 blood is withdrawn, the needle is removed without administration of the dose and the injection site is changed. All kits of study treatment assigned by the IRTwill be recorded/databased in the I RT. The investigator must promote compliance by instructing the patient to take the study treatment exactl y as prescribed and by stating that compliance is necessary for the patient’s safet y and the validity of the study . The patient must also be instructed to contact the investigator if he/she is unable for any reason to take the study treatment ( omalizuamb, placebo, background H1AH or diphenh ydramine )as prescribed . 5.5.5 Permitted dose adjustments and interruptions of study treatment Investigational drug dose adjustments and/or interruptions are not permitted. If a dose (omalizumab or placebo )was dispensed by IRT but not administered to a subject at a visit at which the subject attended, this deviation event must be recorded on the Dosage Administration Record eCRF. 5.5.6 Rescue medication Diphenhy dramine 10 mg or 25 mg tablet will be provided and used on an as-needed basis (up to a maximum of 75 mg/day )during the screening, randomized -treatment, and post-treatment follow -up epochs. Use of rescue medicatio n must be recorded on the Concomitant medications form in the CRF. 5.5.7 Concomitant medication The investigator must instruct the patient to notify the study site about any new medications he/she takes after the patient was enrolled into the study . All medicati ons, procedures and significant non-drug therapies (including physical therapy and blood transfusions ) administered after the patient was enrolled into the study must be recorded in the concomitant medications / significant non-drug therapies eCRF. Each concomitant drug must be individually assessed against all exclusion criteria/prohibited medication. If in doubt the investigator should contact the Novartis medical monitor before randomizing a patient or allowing a new medication to be started. Permitted c oncomitant medications (for CSU) Subjects should remain on a stable non-sedating H1AH treatment regimen throughout the study . During the post-treatment follow -up epoch (after Week 12visit)subjects are permitted to add up to one additional approved non-sedating H1AH or to up-dose the non-sedating H1AH within approved dose levels if multiple doses are available and a lower dose was used as a background therap y. Dosage and administration should follow local regulations."
31,page_31,"Novartis Confidential Page 32 Clinical Trial Protocol (Version 00 ) Protocol No. CIGE025E2305 5.5.8 Prohibited medication Use of the treatments display ed in Table 5-1that could confound the efficacy is NOT allowed during the study for indication and wash -out periods for these treatments are indicated in Table 5 -1. The investigator or authorized site staff must instruct the subject to notify them about any new treatments he/she takes after enrollment. All prohibited treatments taken after enrollment must be recorded in eCRF. If a prohi bited treatment listed in Table 5-1 was used during the study , the subject should discontinue use of the prohibited treatment. At the discretion of the investigator or authorized site staff, if the subject’s use during the study of a prohibited treatment listed in Table 5-1 presents undue safety risk for the subject, the subject should be discontinued from study treatment as per Section 5.5.9. Table 5-1 Prohibited medication Medication Wash out period Anti-IgE therapy No prior use allowed Routine (daily or ever y other day during 5 or more consecutive days )doses of sy stemic corticosteroids 30 days Routine (daily or ever y other day during 5 or more consecutive days )doses of hydroxychloroquine30 days Routine (daily or ever y other day during 5 or more consecutive days )doses of immunosuppression (e.g. methotrexate, cyclosporine, tacrolimus, mycophenolate mofetil, cyclopho sphamide, or triperygium wilfordii Hook )30 days Intravenous immunoglobulin G 30 days Plasmapheresis 30 days Regular (daily or every other day )doxepin (oral) 14 days Any H2antihistamine 7 days Any leukotriene receptor antagonist (LTRA ) 7 days Any H1antihistamine at greater than approved doses 3 days vaccination with inactivated pathogen 48 hours prior to visit s101, 102, and 103 Oral Chinese traditional medicine prescribed for CSU * 30 days Subjects taking either LTRAs or H2 antihistamine for disease other than CSU (e.g., asthma or gastroesophageal reflux disease, respectively )will be permitted to continue their use during the study. These diseases must be recorded as part of the medical history collected during the screening epoch. Inhaled asthma controllers, including corticosteroids, are also permitted during the study . *Subject receiving oral Chines traditional medicine for another indication and for at least 2 months will be allowed to continue this treatment. 5.5.9 Emergency breaking of assigned treatment code Emergency code breaks must only be undertaken when it is required to in order to treat the patient safel y. Most often, study treatment discontinuation and knowledge of the possible treatment assignments are sufficient to treat a study patient who presents with an emergency"
32,page_32,"Novartis Confidential Page 33 Clinical Trial Protocol (Version 00 ) Protocol No. CIGE025E2305 condition. Emergency treatment code breaks are performed using the IRT. When the investigator contacts the system to break a treatment code for a patient, he/she must provide the requested patient identify ing information and confirm the necessity to break the treatment code for the patient. The investigator will then receive details of the investigational drug treatment for the specified patient and a fax or email confirming this information. The system will automatically inform the Novart is monitor for the site and the Study Team that the code has been broken. It is the investigator’s responsibility to ensure that there is a dependable procedure in place to allow access to the IRT/code break cards at any time in case of emergency . The investigator will provide: protocol number study drug name (if available ) patient number In addition, oral and written information to the subject must be provided on how to contact his/her backup in cases of emergency , or when he/she is unavailable, to ens ure that unblinding can be performed at an y time. 5.6 Stud y completion and discontinuation 5.6.1 Study completion and post- study treatment A patient will be considered to have completed the study when the patient has completed the last visit planned in the protoc ol. Continuing care should be provided by investigator and/or referring physician based on patient availability for follow -up. 5.6.2 Discontinuation of study treatment Discontinuation of study treatment for a patient occurs when study drug is stopped earlier th an the protocol planned duration, and can be initiated by either the patient or the investigator. The investigator must discontinue study treatment for a given patient if, on balance, he/she believes that continuation would negativel y impact the risk/bene fit of trial participation. Study treatment must be discontinued under the following circumstances: Patient wish Pregnancy (see Section 6.5.6 and Section 7.6 ) Use of prohibited treatment as per recommendations in Table 5 -1 Any situation in which study participation might result in a safet y risk to the patient Individual serum creatinine increase ≥ 50% compared to baseline, unless the event is not drug related, related to disease progression, or if the benefit / risk assessment supports continuing study treatment. Emergence of the following adverse events: adverse events that in the judgment of the investigator, taking into account the subject’s overall status, prevent the subject from continuing participation in the study (for example, sepsis)"
33,page_33,"Novartis Confidential Page 34 Clinical Trial Protocol (Version 00 ) Protocol No. CIGE025E2305 Any laboratory abnormalities that in the judgment of the investigator, taking into consideration the subject’s overall status, prevents the subject from continuing participation in the study . If discontinuation of study treatment occurs, the patient should NOT be considered withdrawn from the study . The patient should return to the clinic as soon as possi ble, after discontinuation of study drug, for a study treatment discontinuation visit. Treatment discontinuation visit assessments detailed in the “unscheduled treatment discontinuation visit” (UNS )in Table 6-1should be completed and recorded in the eCRF. The investigator must determine the primary reason for the patient’s premature discontinuation of study treatment and record this information on the Dosage Administration eCRF. After study treatment discontinuation, at a minimum, in abbreviated visits, the following data should be collected at clinic visits or via telephone visits: new / concomitant treatments adverse events / serious adverse events If the patient cannot or is unwilling to attend any visit(s), the site staff should maintain regular telephone contact with the patient, or with a person pre-designated by the patient. This telephone contact should preferabl y be done according to the study visit schedule. The investigator must also contact the IRT to register the patient’s discontinuation from study treatment. If study drug discontinuation occurs because treatment code has been broken, please refer to Section 5.5.9 . 5.6.3 Withdrawal of informed consent Patients/subjects may voluntarily withdraw consent to participate in the study for any reason at an y time. Withdrawal of consent from the stud y is defined as when a patient: Does not want to participate in the study anymore and Does not want an y further visits or assessments and Does not want an y further study related contacts and Does not allow anal ysis of already obtained biologic material In this situation, the investigator must make every effort (e.g., telephone, e-mail, letter )to determine t he primary reason for the patient’s decision to withdraw his/her consent and record this information. Study treatment must be discontinued and no further assessments conducted, and the data that would have been collected at subsequent visits will be consi dered missing. Further attempts to contact the patient are not allowed unless safety findings require communicating or follow -up."
34,page_34,"Novartis Confidential Page 35 Clinical Trial Protocol (Version 00 ) Protocol No. CIGE025E2305 All efforts should be made to complete the assessments prior to study withdrawal. A final evaluation at the time of the patie nt’s study withdrawal should be made as detailed in the assessment table below. 5.6.4 Loss to follow -up For subjects whose status is unclear because they fail to appear for study visits without stating an intention to discontinue or withdraw, the investigator should show “due diligence” by documenting in the source documents steps taken to contact the subject, e.g., dates of telephone calls, registered letters, etc. A patient cannot be considered as lost to follow -up until the time point of his/her scheduled end of study visit has passed. 5.6.5 Early study termination by the sponsor The study can be terminated by Novartis at any time for any reason. This may include reasons related to the benefit risk assessment of participating in the study , practical reasons, or for regulatory or medical reasons (including slow enrolment ). Should this be necessary , the patient must be seen as soon as possible and treated as a prematurel y withdrawn patient. The investigator may be informed of additional procedures to be followed in order to ensure that adequate consideration is given to the protection of the patient’s interests. The investigator will be responsible for informing the Institutional Review Board/Independent Ethics Committee (IRBs/IECs )of the early termination of the trial. 6 Visit schedule and assessments Table 6-1lists all of the assessments and indicates with an “x” when the visits are performed , an “s”indicates the data remain in the source documents only . Patients/subjects must be seen for all visits on the designated day,or as close to it as possible. Missed or rescheduled visits should not lead to automatic discontinuation. Patients/subjects who prematurel y discontinue the study for any reason should be scheduled for a visit as soon as possible, at which time all of the assessments listed for the final visit will be performed. At this final visit, all dispensed investigational product should be reconciled and the adverse event and concomitant medications reconciled on the CRF. Patients/subjects will be contacted for safet y evaluations during the 30 days following the last administration of study treatment."
35,page_35,Novartis Confidential Page 36 Clinical Trial Protocol (Version 00 ) Protocol No. CIGE025E2305 Table 6-1 Assessment schedule Epoch Screening Randomized treatment Post -treatment follow -up Visit Number 1 2 101 102 103 199a201 299a Visit Name Week -4 to -2 Week -1 Epoch dispositionRandomization Week 4 Week 8 Week 12 Epoch dispositionWeek 16 Week 20 Epoch disposi tion Day Day -28 to -14Day -7 Day 1 Day 29 Day 57 Day 85 or DISCDay 113 Day 141 or DISC Obtain informed consent x Inclusion/ exclusion criteria x x x In-clinic assessment of UASbx x x Demographic data x Medical/surgical history including urticaria and angioedema history and prior treatmentsx Physical Examcs s s s s s s* Height x Weight x Vital signs x x x x x x x ECG x QuantiFERON®TB-Gold In - Tube testx Chest X -raykx Concomitant medication usagex x x x x x x x* Adverse events x x x x x x x x* Study drug/placebo administrationx x x Randomization x
36,page_36,"Novartis Confidential Page 37 Clinical Trial Protocol (Version 00 ) Protocol No. CIGE025E2305 Epoch Screening Randomized treatment Post -treatment follow -up Visit Number 1 2 101 102 103 199a201 299a Visit Name Week -4 to -2 Week -1 Epoch dispositionRandomization Week 4 Week 8 Week 12 Epoch dispositionWeek 16 Week 20 Epoch disposi tion Day Day -28 to -14Day -7 Day 1 Day 29 Day 57 Day 85 or DISCDay 113 Day 141 or DISC Contact IRT x x x x x Patients ’eDiarydx x x x x x x x* PROs DLQI x x x x* Laboratory tests Serum pregnancy testex Urine pregnancy testex x x x x* Stool ova and parasite evaluationfs Hematologygx x x x x* Chemistryhx x x x x* Urinalysis (local )ix x x Sample collection Anti-omalizumab antibody x x Epoch Depositionlx x x DLQI = Dermatology Life Quality Index NOTE: PROs must be completed prior to other assessments. NOTE: Unless otherwise indicated, all assessments should be performed pre -administration. * These assessments are also to be conducted for patients who discontinue treatment. aSubjects who discontinue study treatment early will be expected to perform 4 weeks after their last dose, the Day 85 (Visit 199) assessments. These subjects will subsequently be expected to perform Post -treatment follow -up the Day 113, 141 evaluations (Visit 201, and 299 ). Subjects who enter the Post -treatment follow -up epoch but wish to terminate early will be expected to perform the Day 141 (Visit 299) assessments."
37,page_37,"Novartis Confidential Page 38 Clinical Trial Protocol (Version 00 ) Protocol No. CIGE025E2305 Epoch Screening Randomized treatment Post -treatment follow -up Visit Number 1 2 101 102 103 199a201 299a Visit Name Week -4 to -2 Week -1 Epoch dispositionRandomization Week 4 Week 8 Week 12 Epoch dispositionWeek 16 Week 20 Epoch disposi tion Day Day -28 to -14Day -7 Day 1 Day 29 Day 57 Day 85 or DISCDay 113 Day 141 or DISC bIn-clinic UAS is assessed by the investigator (for hives) and patient (for itch )at Day -14, Day -7 and Day 1. cPhysical exam on Day -14 is comprehensive but subsequent physical exams maybe limited. dIncludes UAS7 (itch score and number of hives), largest size of hives, , , rescue medication (diphenhydramine ) use, angioedema episodes, calls to doctor or nurse. Daily diary completed twice or once a day by the patient. The eDiary will be given to patients on Day -14, and the patients will be trained by the site staff how to use the eDiary eAll women of childbearing potential (including those who have had a tubal ligation) will have a serum pregnancy test during the screening epoch and urine pregnancy test prior to randomization. If the serum pregnancy test during the screening epoch is positive, the patient will be a screening failure. If urine pregnancy test results are positive during the randomized -treatment epoch, dosing should be held and a serum pregnancy test will be performed by the central laboratory. If urine pregnancy test results are positive during the post -treatment follow -up epoch, a serum pregnancy test will be performed by the central laboratory. Urine pregnancy tests will be performed at the site. fNote that stool ova and parasite examination should be performed on Day -7 in patients with an eosinophil count > 2 times the upper limit of normal on Day -14 AND risk factors for parasitic disease. Stool ova and parasite examination will be performed at t he site. gHemoglobin, hematocrit, platelet count, RBC count, W BC count, percent and absolute differential count (neutrophils, bands, eosinophils, lymphocytes monocytes, basophils other cells ). hSodium, potassium, chloride, bicarbonates, glucose, BUN, cre atinine, calcium, phosphorus, magnesium, total and direct bilirubin, total protein, albumin, ALT, AST, LDH, alkaline phosphatase, creatinine phosphokinase, and uric acid. i A midstream urine sample (approximately 30 mL) will be obtained, in order to avoid contamination with epithelial cells and sediments, and allow proper assessments. Semi quantitative ‘dipstick’ evaluation for the following parameters will be performed. Specific gravity, pH, glucose, protei n, bilirubin, ketones, nitrite, leucocyte and bloo d. KChest X ray will be performed only in case of positive QFT l If the patient will continue into the next phase of the trial or if the study is terminated by the sponsor at any ti me for any reason, the patient are expected to perform the assessment at the last visit of each respective epoch. Epoch disposition page may look slightly different in the content depending the epoch."
38,page_38,"Nova rtis Confidential Page 39 Clinical Trial Protocol (Version 00 ) Protocol No. CIGE025E2305 6.1 Information to be collected on screening failures All patients/subjects who have signed informed consent but not entered into the next epoch will have the study completion page for the screening epoch, demographics, inclusion/exclusion, and serious adverse event (SAE )data collected. Adverse events that are not SAEs will be followed by the investigator and collected onl y in the source data. 6.2 Patient demographics/other baseline characteristics Patient demographic and baseline characteristic data to be collected on all patients include date of birth, age, sex, race, ethnicit y. Relevant medical history /current medical condition present before signing the informed consent will be captured. Where possible, diagnoses, and not symptoms, will be recorded. In addition, data on patient’s family history on malignancie s is collected on the respective CRF page to assess possible risk factors related to any malignancies. 6.2.1 Tuberculosis screening and management 6.2.1.1 QuantiFERON TB -Gold In -tube assay A QFT to screen a population for latent tuberculosis infection (Dohert y et al 2008) will be used at screening to evaluate the subjects’ eligibility for the study . This blood -based assay is specific for Mycobacterium tuberculosis and is not influenced by pr evious Bacillus Calmette - Guérin vaccination or by exposure to other Mycobacteria species. Furthermore, this test, in contrast to the purified protein derivative (PPD)skin test, is also insensitive to a booster effect since the subject is not exposed to the vaccine. The assay measures the production of interferon -gamma and presents it relative to a negative and a positive control sample (Manuel and Kumar 2008) . The QFT kit will be supplied by the central laboratory . Details on the collection, shipment of samples and reporting of results by the central laboratory are provided to investigators in the study -specific laboratory manual. 6.2.1.2 Chest X -ray For patients with a positive QFT, a chest X-ray is required; no new chest X-ray is needed in subjects with chest X-ray, chest CT scan and/or chest MRI performed within 12 weeks of screening. If the chest X-ray, chest CT scan, and/or chest MRI evaluated by a qualified health care professional reveals past or present active TB, the subject will not be enrolled into the study . 6.2.1.3 Protocol for tuberculosis screening Screening for TB will be performed according toFigure 6-1, below. Positive or indeterminate QFTs must be entered on the Tuberculosis assessment eCRF."
39,page_39,"Nova rtis Confidential Page 40 Clinical Trial Protocol ( Version 00 ) Protocol No. CIGE025E2305 Figure 6-1 Tuberculosis screening flowchart The approach to screening is as follows: If the QFT result is negative, the subject may be randomized. If the QFT result is positive , the investigator should perform further evaluation to rule out active TB, as per local procedures. If a TB workup was conducted prior to screening the"
40,page_40,"Nova rtis Confidential Page 41 Clinical Trial Protocol (Version 00 ) Protocol No. CIGE025E2305 subject, results of the workup can be used to assess eligibility if the workup was conducted within 12 weeks prior to randomization. oSubjects with latent TB may be randomized if treatment for latent TB has been performed for 4 weeks prior to randomization and subject agrees to continuous treatment according to local guidelines. oSubjects positive for active TB per workup are not eligible for the study . If the QFT result is indeterminate , the investigator may repeat the test once or may proceed directly to perform workup for TB as per local procedures. This action is at the discretion of the investigator. If a TB workup was conducted prior to the screening the subject, results of the workup can be used to assess eligibility if the workup was conducted within 12 weeks prio r to randomization. oIf the second test is negative , the subject may be randomized. oIf the second test is positive or indeterminate , the investigator should perform further evaluation to rule out active TB, as per local guidelines. Subject positive for latent TB per workup may be randomized to the trial if treatment for latent TB has been performed for 4 weeks prior to randomization and subject agrees to continuous treatment according to local guidelines. Subjects positive for active TB per workup arenot eligible for the study . If eligibility is being assessed with only 1 test result and a TB workup (i.e., no second TB test will be performed ), the TB test to assess eligibility must have been done via the central laboratory for the study within the screening epoch (within 4 weeks prior to randomization) and TB workup will only be considered if it was completed within 12 weeks prior to randomization. Subjects positive for latent TB per workup may be randomized to the trial if sufficient treatment has been initiated according to local routine clinical practice for at least 4 weeks prior to randomization and will be maintained for the prescribed duration. Subjects positive for active TB per workup are not eligible for the study . Subjects negative for TB per workup (no signs of latent or active TB)may be randomized to the trial. 6.2.1.4 Treatment of latent TB and safety monitoring In case of latent TB, patients who elect to remain in the trial will receive TB proph ylaxis treatment according to local guidelines. T he following recommendations are based on WHO guidelines and are considered guidance, unless local regulations suggest different approaches. If a 6 month 5 mg/kg/per day INH TB proph ylaxis is prescribed according WHO guidelines used in China (WHO 2015) , patients are required to undergo monthly LFT monitoring. The INH treatment will be continued for 6 months. The INH treatment should be halted in the following situations: ALT ≥ 5 x ULN ALT ≥ 3 x ULN and presence of symptoms (e.g. general malaise, fatigue, abdominal pain, nausea, or vomiting )"
41,page_41,"Nova rtis Confidential Page 42 Clinical Trial Protocol (Version 00 ) Protocol No. CIGE025E2305 ALT ≥ 2-3 x UL N and AST ≥ 3 x UL N In patients whose INH is discontinued, after ALT normalization, TB prophy laxis will be resumed with an alternative regimen (e.g., 10 mg/kg/p er day rifampicin )for 3 -4 months. If regimens that don’t include INH are chosen to treat latent TB, then monitoring of LFTs will be necessary in the case of regimens including rifam ycins (e.g., rifampicin, rifapentine, or rifabutine ), pyrazinamide, or their analogs; in such cases, management of abnormal LFTs should be performed using the example for INH, above. 6.2.2 Other baseline characteristics Baseline characteristic data to be collected on all subjects include (all laboratory results are central except where indicated ): ECG, vital signs; hematology ; clinical chemistry ; local urinaly sis; local stool ova and parasite evaluation; serum pregnancy test; medical history of anaph ylactic; history of contraindications to diphenhydramine ; immunogenicity ; in clinic UAS; DL QI. 6.3 Treatment exposure and compliance All doses of study treatment administration will be recorded on the appropriate Dosage Administration Record eCRF page. Compliance will be assessed by unblinded field monitor at each visit using vials (omal izumab and omalizumab placebo) counts and information provided by the unblinded pharmacist or unblinded authorized site staff responsible for treatment dispensation and preparation. 6.4 Efficacy A number of efficacy variables will be assessed during the study . During each visit, the assessment will be started with patient reported outcomes (PRO) (DLQI )and then move to other assessments and laboratory assessment. 6.4.1 eDiary assessments 6.4.1.1 Number of hives, intensity of itch, and Urticaria A ctivity Score ( UAS) The numb er of hives, and intensity of itch score will be recorded by the patient twice daily (morning and evening )in their eDiary, on a scale of 0 (none) to 3 (intense/severe) ( see Table 6-2). The UAS is a composite score of the number of wheals (hives ) (Hives Severit y Scores, HSS ); and the severity of the itch (Itch Severity Scores, ISS ). Table 6-2 Urticaria A ctivity Score (UAS) Score Wheals ( Hives ) Pruritu s (Itch) 0 None None 1 Mild (1- 6 hives/12 hours ) Mild ( minimal awareness, easily tolerated ) 2 Moderate (7-12/12 hours ) Moderate (definite awareness, bothersome but tolerable ) 3 Severe (> 12 hives/12 hours ) Severe ( difficult to tolerate )"
42,page_42,"Nova rtis Confidential Page 43 Clinical Trial Protocol (Version 00 ) Protocol No. CIGE025E2305 6.4.1.1.1 Hives Severity Score ( HSS) The wheals (hives )severity score (HSS), defined by number of hives, will be recorded by the patient twice daily in their eDiary , on a scale of 0 (none) to 3 (intense/severe ) (see Table 6 -2). Aweekl y score (HSS7 )is derived by adding up the average daily scores of the 7 days preceding the visit. The possible range of the weekly score is therefore 0 – 21. Complete hives response is defined as HSS7 = 0. When either the morning or evening score is missing, the non-missing score for that day (morning or evening )will be used as the daily score. When one or more of the daily scores are missing, the following principles will be applied to handle the mis sing data: If a patient has at least 4 non-missing daily scores within the 7 days prior to the study visit, theweekl y score is calculated as the sum of the available eDiary scores in that week, divided bythe number of days that have a non-missing diary score, multiplied by 7. If there are less than 4 non-missing daily scores within the prior 7 day s, then the weekly score is missing for the week. 6.4.1.1.2 Itch Severity Score (ISS) The severity of the itch will be recorded by the patient twice daily in their eDiary , on a scale of 0 (none) to 3 (intense/severe) ( see Table 6-2). A weekl y score (ISS7 )is derived by adding up the average daily scores of the 7 day s preceding the visit. The possible range of the weekly score is therefore 0 –21. Partially missing diary entries will be handled in the same way as described for the hives severity score. Complete itch response is defined as ISS7 = 0. Weekly itch severit y score MID response is defined as a reduction from basel ine in weekly itch severit y score of at least 5 points. Time to weekly itch severity score MID response is the time (in weeks )from the date of the first dose to the date where weekly itch severit y score MID response is first achieved. 6.4.1.1.3 The weekly Urticaria Activity Score (UAS7 ) The UAS7 is the sum of the HSS7 score and the ISS7 score. The possible range of the weekly UAS7 score is 0 – 42. Complete UAS7 response is defined as UAS7 = 0. UAS7 MID response is defined as a reduction from baseline in UAS7 of at least 11 points. Time to UAS7 MID response is the time (in weeks) from the date of the first dose to the date where UAS7 MID response is first achieved. Week 12 responders are defined as patients who achieve an absolute UAS7 less than or equal to 6 at Week 12."
43,page_43,Nova rtis Confidential Page 44 Clinical Trial Protocol (Version 00 ) Protocol No. CIGE025E2305
44,page_44,"Nova rtis Confidential Page 45 Clinical Trial Protocol (Version 00 ) Protocol No. CIGE025E2305 6.4.1.6 Calls to doctor or nurse Calls to doctor, nurse or nurse practitioner because of the patient ’s skin condition will be recorded once dail y in the eDiary b y the patient. 6.4.2 Patient reported outcome assessment 6.4.2.1 Dermatology Life Quality Index ( DLQI ) DLQI is a 10-item dermatology -specific health -related quality of life measure (Finlay and Khan 1994) . Patients rate their dermatology symptoms as well as the impact of their skin condition on various aspects of their lives. An overall score will be calculated as well as separate scores for the following domains: Symptoms and Feelings, Daily Activities, Leisure, Work and School, Personal Relationships, Treatment. The minimally important difference of the overall DLQI score for patients with CSU has been estimated to be 2.24−3.10 (Shikiar et al 2005) .DLQI questionnaire will be provided in Chinese language, and be assessed at the site; The questionnaire will be completed by the patients unobserved. 6.4.3 Appropriateness of efficacy assessments Efficacy will be determined using the primary endpoint of change from baseline in the weekl y itch severit y score at Week 12. Assessment of itch is the symptom of greatest concern to patients, with greatest impact on their qualit y of life (Mathias et al 2010) . Because the chief CSU symptoms are hives and intense itch, it is appropriate to evaluate clinical response through use of the UAS, a composite endpoint that measures both of these symptoms. UAS7 is therefore incorporated as a secondary endpoint. Time to onset of the clinical effect (ISS7 MID and UAS7 MID )of treatment with omalizumab will be evaluated during the treatment epoch. Time to onset of clinical effect is important to establish so that guidance can be given to patients regarding when a response should be expected. Disease recurrence after study drug is withdrawn will be measured during this study . For all patients, symptom scores will be measured during both the treatment and post-treatment follow -up epochs. This important information will be used along with data from other studies to provide guidance for the duration of therap y. 6.5 Safet y 6.5.1 Physical examination A complete physical examination will include the examination of general appearance, skin, neck (including thyroid) , eyes, ears, nose, throat, lungs, heart, abdomen, back, lymph nodes, extremities, vascular and neurological. If indicated based on medical history and/or sy mptoms, rectal, external genitalia, breast, and pelvic exams will be performed. A short physical exam will include the examination of general appearance and vital signs (blood pressure [SBP and DBP] and pulse ). A short phy sical exam will be at all visits starting from visit 3 except where a complete ph ysical examination is required (see above )."
45,page_45,"Nova rtis Confidential Page 46 Clinical Trial Protocol (Version 00 ) Protocol No. CIGE025E2305 Information for all phy sical examinations must be included in the source documentation at the study site. Clinically relevant findings that are present prior to signing informed consent must be included in the Medical History part of the CRF. Significant findings made after first administration of investigational drug which meet the definition of an Adverse Event must be recorded on the Adverse Event section of the CRF. 6.5.2 Vital signs Vital signs include BP and pulse measurements. After the patient has been sitting for five minutes, with back supported and both feet placed on the floor, systolic and diastolic blood pressure will be measured using an automated validated device, e.g., OMRON, with an appropriatel y sized cuff. In case the cuff sizes available are not large enough for the patient’s arm circumference, a sphygmomanometer with an appropriatel y sized cuff may be used. Clinically notable vital signs are defined in Appendix 1 . 6.5.3 Height and weight Height in centimeters (cm)and body weight (to the nearest 0.1 kilogram (kg)in indoor clothing, but without shoes ) will be measured. 6.5.4 Laboratory evaluations A central laboratory will be used for analy sis of all specimens collected. Details on the collections, shipment of samples and reporting of results by the central laboratory are provided to investigators in the laboratory manual. Clinically notable laboratory findings are defined in Appendix 1 . 6.5.4.1 Hematology Hemoglobin, hematocrit, red blood cell count, white blood cell count with differential counts, and platelet count will be measured. 6.5.4.2 Clinical chemistry Sodium, potassium, chloride, bicarbonates, glucose, BUN, creatinine, calcium, phosphorus, magnesium, total and direct bilirubin, total protein, albumin, ALT, AST, LDH, alkaline phosphatase, creatinine phosphokinase, and uric acid will be measured. 6.5.4.3 Urinaly sis A midstream urine sample (approximately 30 ml) will be obtained, in order to avoid contamination with epithelial cells and sediments, and allow proper assessments. Semi quantitative 'dipstick' evaluation for the following parameters will be performed. Specific gravity , pH, glucose, protein, bilirubin, ketones, nitrite, leucocy te and blood. 6.5.4.4 Anti-omalizumab antibodies At Visit 101 an anti-omalizumab antibody level will be measured on all patients prior to first dosing. Patients are also instructed to return to the clinic for an anti-omalizumab antibody blood sample 12 weeks after their last administration (Visit 299 ). The 12-week waiting period"
46,page_46,"Nova rtis Confidential Page 47 Clinical Trial Protocol (Version 00 ) Protocol No. CIGE025E2305 decreases the interference of anti-omalizumab antibody detection due to the presence of omalizumab. Refer to the blood log inAppendix 2, Table 13-2 for sample collection and volumes. 6.5.5 Electrocardiogram (ECG ) ECGs must be recorded after 10 minutes rest in the supine position to ensure a stable baseline . The preferred sequence of cardiovascul ar data collection during study visits is ECG collection first, followed by vital signs, and blood samplin g. The Fridericia QT correction formula (QTcF )should be used for clinical decisions. Single 12 lead ECGs are collected. The original ECGs and a certified copy on non- heat sensitive paper, appropriately signed, must be collected and archived at the study site. Each ECG tracing must be labeled with study number, subject initials, subject number, date and time, and filed in the study site source documents. For any ECGs with subject safet y concerns, two additional ECGs must be performed to confirm the safet y finding. Clinicall y significant ECG findings at baseline must be discussed with the sponsor before administration of study treatment. Clinically significant abnormalities must be recorded on the relevant section of the medical history /Current medical conditions/AE CRF / e (CRF )page as appropriate. 6.5.6 Pregnancy and assessments All pre-menopausal women who are not surgically sterile will have pregnancy testing. Additional pregnancy testing might be performed if requested by local requirement s. Any females with a confirmed serum positive pregnancy test during screening are not eligible for randomization. All pre-menopausal females who are not sterile at screening will also have a urine pregnanc y test performed locall y at Visits 101, 102, 103, 199 and 299. A positive urine pregnancy test during the treatment epoch of the study requires immediate interruption of study treatment until serum β-hCG is performed and found to be negative. If the serum β-hCG test is positive, study treatment must be discontinued, as described in Section 5.5.9. 6.5.7 Appropriateness of safety measurements The safet y assessments selected in this study are reliable and standard measured for a biologic immunomodulating agent in adult and adolescent subjects with CSU."
47,page_47,"Nova rtis Confidential Page 48 Clinical Trial Protocol (Version 00 ) Protocol No. CIGE025E2305 7 Safety monitoring 7.1 Adverse events An adverse event (AE)is any untoward medical occurrence (e.g., any unfavora ble and unintended sign [including abnormal laboratory findings], sy mptom or disease )in a subject or clinical investigation subject after providing written informed consent for participation in the study until the end of study visit. Therefore, an AE may or may not be temporally or causall y associated with the use of a medicinal (investigational )product. In addition, all reports of intentional misuse and abuse of the product are also considered an adverse event irrespective if a clinical event has occurred. The occurrence of adverse events must be sought by non-directive questioning of the patient at each visit during the study . Adverse events also may be detected when they are volunteered by the patient during or between visits or through physical examina tion findings, laboratory test findings, or other assessments. Abnormal laboratory values or test results constitute adverse events only if they fulfill at least one of the following criteria: they induce clinical signs or sy mptoms, they are considered clinically significant, they require therapy . Clinically significant abnormal laboratory values or test results must be identified through a review of values outside of normal ranges/clinically notable ranges, significant changes from baseline or the previous visit, or values which are considered to be non-typical in patient with underly ing disease. Investigators have the responsibility for managing the safet y of individual patient and identify ing adverse events. Alert ranges for labor atory and other test abnormalities are included in Appendix 1. Adverse events must be recorded in the Adverse Events CRF under the signs, symptoms or diagnosis associated with them, accompanied by the following information: the severit y grade mild: usually transient in nature and generally not interfering with normal activities moderate: sufficiently discomforting to interfere with normal activities severe: prevents normal activities its relationship to the study treatment Yes No its duration ( start and end dates) or if the event is ongoing an outcome of not recovered/not resolved must be reported."
48,page_48,"Nova rtis Confidential Page 49 Clinical Trial Protocol (Version 00 ) Protocol No. CIGE025E2305 whether it constitutes a serious adverse event ( SAE -See Section 7.2 for definition of SAE ) and which seriousness criteria have been met. action taken regarding [investigational] treatment All adverse events must be treated appropriately . Treatment may include one or more of the following: no action taken (e.g. further observation only ) investigational treat ment interrupted/withdrawn concomitant medication or non- drug therap y given non-drug therap y given patient hospitalized/patient’s hospitalization prolonged (see Section 7.2 for definition of SAE ) its outcome (not recovered/not resolved; recovered/resolved; recovering/resolving, recovered/resolved with sequelae; fatal; or unknown ) Once an adverse event is detected, it must be followed until its resolution or until it is judged to be permanent, and assess ment must be made at each visit (or more frequently , if necessary ) of any changes in severity , the suspected relationship to the study drug, the interventions required to treat it, and the outcome. Information about common side effects alread y known about the investigational drug can be found in the Investigator Brochure (IB). This information will be included in the patient informed consent and should be discussed with the patient during the study as needed. Any new information regarding the safet y profile of the medicinal product that is identified between IB updates will be communicated as appropriate, for example, via an Investigator Notification (IN) or an Aggregate Safet y Finding. New informatio n might require an update to the informed consent and has then to be discussed with the patient. The investigator must also instruct each patient to report any new adverse event (beyond the protocol observation period )that the patient, or the patient’s personal physician, believes might reasonabl y be related to study treatment. This information must be recorded in the investigator’s source documents; however, if the AE meets the criteria of an SAE, it must be reported to Novartis. 7.2 Serious adverse events 7.2.1 Definition of SA E An SAE is defined as any adverse event [appearance of (or worsening of any pre-existing )] undesirable sign(s), symptom (s)or medical conditions(s) which meets any one of the following criteria: is fatal or life -threatening results in persistent or significant disability /incapacity constitutes a congenital anomaly /birth defect requires inpatient hospitalization or prolongation of existing hospitalization, unless hospitalization is for:"
49,page_49,"Nova rtis Confidential Page 50 Clinical Trial Protocol (Version 00 ) Protocol No. CIGE025E2305 routine treatment or monitoring of the studied indi cation, not associated with any deterioration in condition (specify what this includes) elective or pre -planned treatment for a pre -existing condition that is unrelated to the indication under study and has not worsened since signing the informed consent treatment on an emergency outpatient basis for an event not fulfilling any of the definitions of a SAE given above and not resulting in hospital admission social reasons and respite care in the absence of any deterioration in the patient’s general condition is medically significant, e.g. defined as an event that jeopardizes the patient or may require medical or surgical intervention. All malignant neoplasms will be assessed as serious under “medically significant” if other seriousness criteria are not met. Life-threatening in the context of a SAE refers to a reaction in which the patient was at risk of death at the time of the reaction; it does not refer to a reaction that hypothetically might have caused death if it were more severe (please refer to Annex I V, ICH -E2D Guideline ). Medical and scientific judgment should be exercised in deciding whether other situations should be considered serious reactions, such as important medical events that might not be immediately life threatening or result in death or hospitalization but might jeopardize the patient or might require intervention to prevent one of the other outcomes listed above. Examples of such events are intensive treatment in an emergency room or at home for allergic bronchospasm, blood dyscrasias or convulsions that do not result in hospitalization or development of dependency or abuse ( please refer to Annex I V, ICH-E2D Guideline ). Any suspected transmission via a medicinal product of an infectious agent is also considered a serious adverse reaction. 7.2.2 SAE reporting To ensure patient safet y, every SAE, regardless of causalit y, occurring after the patient has provided informed consent and until 30 days after the last study visitmust be reported to Novartis within 24 hours of learning of its occurrence. A ny SAEs experienced after the 30 day period after the last study visit should only be reported to Novartis if the investigator suspects a causal relationship to study treatment. All follow -up information for the SAE including information on complications, progression of the initial SAE and recurrent episodes must be reported as follow -up to the original episode within 24 hours of the investigator receiving the follow -up information. An SAE occurring at a different time interval or otherwise considered comp letely unrelated to a previously reported one must be reported separatel y as a new event. Information about all SAEs is collected and recorded on the Serious Adverse Event Report Form; all applicable sections of the form must be completed in order to provide a clinically thorough report. The investigator must assess the relationship of each SAE omalizumab and complete the SAE Report Form in English, and submit the completed form within 24 hours to Novartis. Detailed instructions regarding the submissio n process and requirements for signature are to be found in the investigator folder provided to each site."
50,page_50,"Nova rtis Confidential Page 51 Clinical Trial Protocol (Version 00 ) Protocol No. CIGE025E2305 Follow -up information is submitted as instructed in the investigator folder. Each re- occurrence, complication, or progression of the original event must be reported as a follow -up to that event regardless of when it occurs. The follow -up information should describe whether the event has resolved or continues, if and how it was treated, whether the blind was broken or not, and whether the patient conti nued or withdrew from study participation. If the SAE is not previously documented in the Investigator’s Brochure or Package Insert (new occurrence )and is thought to be related to the study treatment a Drug Safet y and Epidemiology Department associate may urgently require further information from the investigator for health authority reporting. Novartis may need to issue an Investigator Notification (IN)to inform all investigators involved in any study with the same study treatment that this SAE has been reported. Suspected Unexpected Serious Adverse Reactions (SUSARs) will be collected and reported to the competent authorities and relevant ethics committees in accordance with EU Guidance 2011/C 172/01 or as per national regulatory requirements in particip ating countries. 7.3 Liver safety monitoring As omalizumab is not associated with hepatotoxic potential no specific liver safet y monitoring is needed in this trial in patients who do not require treatment for latent TB. 7.4 Renal safety monitoring As omalizumab is not associated with kidney toxicity potential no specific renal safet y monitoring is needed in this trial. 7.5 Reporting of study treatment errors including misuse/abuse Medication errors are unintentional errors in the prescribing, dispensing, administrat ion or monitoring of a medicine while under the control of a healthcare professional, patient or consumer ( EMA definition). Misuse refers to situations where the medicinal product is intentionally and inappropriatel y used not in accordance with the protocol. Abuse corresponds to the persistent or sporadic, intentional excessive use of a medicinal product, which is accompanied by harmful ph ysical or psy chological effects. Study treatment errors and uses outside of what is foreseen in the protocol will be collected in thedose administration record (DAR )eCRF irrespective of whether or not associated with an AE/SAE and reported to Safety only if associated with an SAE. Misuse or abuse will be collected and reported in the safety database irrespective ofit being associated with an AE/SAE."
51,page_51,"Nova rtis Confidential Page 52 Clinical Trial Protocol (Version 00 ) Protocol No. CIGE025E2305 Table 7- 1 Guidance for capturing the study treatment errors including misuse/abuse Treatment error typeDocument in Dose Administration (DAR) eCRF (Yes/No )Document in A E eCRFComplete SA E form Unintentional study treatment errorYes Only if associated with an AEOnly if associated with an SAE Misuse/Abuse Yes Yes Yes, even if not associated with a SAE 7.6 Pregnancy reporting To ensure patient safet y, each pregnancy occurring after signing the informed consent must be reported to Novartis within 24 hours of learning of its occurrence. The pregnancy should be followed up to determine outcome, including spontaneous or voluntary termination, details of the birth, and the presence or absence of any birth defects, congenital abnormalities, or maternal and/or newborn complications. Pregnancy must be recorded on the Pharmacovigilance Pregnancy Form and reported by the investigator to the local Novartis Drug Safet y and Epidemiology Department. Pregnancy follow -up should be recorded on the same form and should include an assessment of the possible relationship to the study treatment. Any SAE experienced during the pregnancy and unrelated to the pregnancy must be reported on a SAE form. 8 Data revie w and database management 8.1 Site monitoring Before study initiation, at a site initiation visit or at an investigator’s meeting, a Novartis representative will review the protocol and CRFs with t he investigators and their staff. During the study , Novartis employ s several methods of ensuring protocol and GCP compliance and the quality /integrity of the sites’ data. The field monitor will visit the site to check the completeness of patient records, the accuracy of entries on the (e)CRFs, the adherence to the protocol and to Good Clinical Practice, the progress of enrollment, and to ensure that study treatment is being stored, dispensed, and accounted for according to specifications. Key study personne l must be available to assist the field monitor during these visits. Continuous remote monitoring of each site’s data may be performed by a centralized Novartis CRA organization. Additionally , a central analy tics organization may analyze data, identify risks and trends for site operational parameters, and provide reports to Novartis Clinical Teams to assist with trial oversight. The investigator must maintain source documents for each patient in the study , consisting of case and visit notes (hospital or clinic medical records )containing demographic and medical information, laboratory data, electrocardiograms, and the results of any other tests or"
52,page_52,"Nova rtis Confidential Page 53 Clinical Trial Protocol (Version 00 ) Protocol No. CIGE025E2305 assessments. All information on CRFs must be traceable to these source documents in the patient's file. The investigator must also keep the original informed consent form signed by the patient (a signed copy is given to the patient ). The investigator must give the monitor access to all relevant source documents to confirm their consistency with the CRF entries. Novartis monitoring standards require full verification for the presence of informed consent, adherence to the inclusion/exclusion criteria, documentation of SAEs, and of data that will be used for all primary variables. Additional checks of the consistency of the source data with the CRFs are performed according to the study -specific monitoring plan. No information in source documents about the identity of the patients/subjects will be disclosed. 8.2 Data collection Novartis will suppl y the investigator site with a computer loaded with Electronic Data Capture (EDC )software that has been fully validated and conforms to US CRF 21 Part 11 requirements. Investigator site staff will not be given access to the EDC system until they have been trained by Novartis personnel. Designated investigator staff will enter the data required by the protocol into the Novartis CRFs using the Novartis -supplied computer. Automatic validation programs check for data discrepancies in the CRF s and, by generating appropriate error messages, allow the data to be confirmed or corrected by the investigator staff before transfer of the data to Novartis via a secure Virtual Private Network. The investigator must certify that the data entered are complete and accurate by signing a memo generated at the end of the trial that will be sent to him by Novartis personnel. After database lock, the investigator will receive copies of the patient data for archiving at the investigational site. 8.3 Database managem ent and quality control Novartis staff [or CRO working on behalf of Novartis] review the data entered into the CRFs by investigational staff for completeness and accuracy and instruct the site personnel to make any required corrections or additions. Queri es are sent to the investigational site using an electronic data query . Designated investigator site staff is required to respond to the query and confirm or correct the data. If the electronic query system is not used, a paper Data Query Form will be faxe d to the site. Site personnel will complete and sign the faxed copy and fax it back to Novartis staff that will make the correction to the database. The signed copy of the Data Query Form is kept at the investigator site. Concomitant medications entered into the database will be coded using the WHO Drug Reference List, which employ s the Anatomical Therapeutic Chemical classification system. Concomitant procedures, non-drug therapies and adverse events will be coded using the Medical dictionary for regulator y activities (MedDRA )terminology . Laboratory samples will be processed centrall y and the results will be sent electronicall y to Novartis ( or a designated CRO ). Diary data will be entered into an electronic diary by the patient OR Patients/subjects will fill in their patient reported outcome (PRO )data in a site based tablet. The system will be"
53,page_53,"Nova rtis Confidential Page 54 Clinical Trial Protocol (Version 00 ) Protocol No. CIGE025E2305 supplied by a vendor (s), who will also manage the database. The databa se will be sent electronically to Novartis personnel ( or designated CRO ) . Randomization codes and data about all study drug(s)dispensed to the patient and all dosage changes will be tracked using an Interactive Response Technology (IRT). The system will be supplied by a vendor, who will also manage the database. The database will be sent electronically to Novartis (or a designated CRO ). Each occurrence of a code break via IRT will be reported to the clinical team and monitor. The code break functionality will remain available until study shut down or upon request of Novartis. The occurrence of relevant protocol deviations will be determined. After these actions have been completed and the database has been declared to be complete and accurate, it will be locked and the treatment codes will be unblinded and made available for data analysis. Any changes to the database after that time can only be made after written agreement by Novartis Development management. 8.4 Data Monitoring Committee Not required. 8.5 Adjudic ation Committee An independent adjudication committee will be used to monitor anaph ylaxis. The events will be reviewed in a blinded manner and adjudicated as they occur during the conduct of the study . Details regarding the adjudication process are availa ble in the relevant Anaph ylaxis Adjudication Committee charter. 9 Data analy sis The analysis will be conducted on all subject data at the time the trial ends. Any data analysis carried out independently by the investigator should be submitted to Novartis before publication or presentation. 9.1 Analysis sets Randomized population (RAN) : The RAN will include all randomized subjects, regardless of whether they took any study medication. Patients in RAN will be analy zed according to the treatment assigned at random ization. Full analysis set (FAS ): The FAS will include all randomized subjects who receive at least one dose of study drug. Following the intent -to-treat principle, subjects will be analyzed according to the treatment they are assigned to at randomization. This analysis population will be used for all efficacy analy ses unless otherwise specified. Safety set (SAF ): The SAF consists of all subjects in the FAS who take at least one dose of study medication. Subjects will be analy zed according to the actual treatment received during the randomized treatment epoch, as follows:"
54,page_54,"Nova rtis Confidential Page 55 Clinical Trial Protocol (Version 00 ) Protocol No. CIGE025E2305 Placebo: Patients who received only placebo injections (i.e., no active treatment )during the randomized treatment epoch 150mg omalizumab: Patients who received at least one 150mg omaliz umab injection but no higher active dose level (i.e., 300mg)injections during the randomized treatment epoch 300mg omalizumab: Patients who received at least one 300mg omalizumab injection during the randomized treatment epoch . 9.2 Patient demographics and other baseline characteristics The anal ysis will be based on the RAN, unless otherwise specified. Demographic and baseline characteristics Summary statistics will be presented for continuous demographic and baseline characteristic variables for each treatment group. The number and percentage of patients in each category will be presented for categorical variables for each treatment group and all patients. The randomized treatment groups will be summarized by the following demographic variables: gender, age, ethnicity , race, weight, height, and BMI. Baseline disease characteristics will also be summarized for the following variables, including but not limited to: duration of CSU, previous number of CSU medications, previous use of systemic steroids for CS U, in -clinic UAS, weekly urticaria activity score (UAS7 ), weekly itch severit y score (ISS7), weekly number of hives score (NHS7 ) , weeklysize of largest hive score (LHS7 ), and presence of angioedema . Medical history Any condition entered on the Medical his tory eCRF will be coded using the MedDRA dictionary . The number of patients with medical history will be summarized by primary system organ class, preferred term and treatment group for the RAN. Protocol solicited medical history will be also summarized. 9.3 Treatments The anal ysis of study treatment data will be based on the SAF, unless otherwise specified. Study treatment The duration of exposure to study treatment will be summarized by treatment group. In addition, the number of doses and total cumulative dosage will be presented. Duration of exposure is defined as the date of the last treatment minus the date of first study drug administration plus 4 weeks (28 day s). Prior and concomitant medication Prior medications are defined as treatments taken and stopped prior to first dose of study treatment. Any medication given at least once between the day of first dose of randomized"
55,page_55,"Nova rtis Confidential Page 56 Clinical Trial Protocol (Version 00 ) Protocol No. CIGE025E2305 study treatment and the date of the last study visit will be a concomitant medication, including those which were started pre-baselin e and continued into the period where study treatment is administered. Prior and concomitant medications will be summarized by treatment separately for CSU related and non-CSU related medications. CSU - related medications will be summarized by pre-specified categories, route of administration, and preferred term. Non-CSU related concomitant medications will be summarized by the preferred term. Concomitant medications will be also summarized by epoch; the randomized treatment epoch and newly onset during post-treatment follow -up epoch. Significant surgery and medical procedures will be summarized by primary system organ class and MedDRA preferred term. 9.4 Analysis of the primary variable (s) Analy ses will be based on the patients in FAS, unless otherwise specified. 9.4.1 Variable (s) The primary efficacy variable is change from baseline in weekly itch severity score (ISS7, a component of the UAS7, see Section 6.4.1.1) at Week 12. The daily itch score is the average of the morning and evening itch severit y scores. The baseline ISS7 is the sum of the daily itch severity scores over the 7 days prior to the randomization Day 1 visit, and the ISS7 at Week 12 is the sum of daily itch scores over the 7 days prior to the Week 12 visit. The same principles of calculating baseline and Week 12 weekl y scores will be applied to each weekl y outcome unless otherwise stated . 9.4.2 Statistical model, hypothesis, and method of analy sis Amixed -effect linear model with repeated measures (MMRM) will be used to obtain the least squares mean (LSM )estimate for each treatment group for change from baseline in ISS7 at Week 12 (the primary endpoint ). The MMRM model will include terms of treatment group, week (1 to 12), baseline score, baseline score -by- week interaction, and treatment -by-week interaction as fixed effects. Treatment group and week will be fitted as categorical variables, and baseline score as a continuous covariate . The within -patient correlation will be modeled using the unstructured covariance matrix (Mallinc krodt et al 2001). If the model does not converge, the compound symmetry covariance structure will be used. The occurrence of missing data will be assumed to be missing at random ( MAR ). The difference in LSM estimates between treatment groups, together with a 95% CI, will be presented. A multiplicity adjustment for two primary efficacy comparisons based on above model will be made according to the overall study testing strategy provided in Section 9.5.1 . The statistical analyses will test the null hypothesis of no difference between the placebo and each omalizumab dose group."
56,page_56,"Nova rtis Confidential Page 57 Clinical Trial Protocol (Version 00 ) Protocol No. CIGE025E2305 9.4.3 Handling of missin g values/censoring/discontinuations The primary endpoint will be analy zed using an MMRM which is valid under the MAR (Missing -At-Random )assumption (Rubin 1976). Patients who have at least one post-baseline are included in the MMRM analysis. This includes not only the patients who have completed 12 weeks of treatment (with a complete 12-week longitudinal data) , but also those who discontinue from study treatment early (although only able to contribute to a partial time profile ). This is under the assumption that dropouts would follow the similar data pattern like other patients who complete the treatment period in the same treatment group, as if they had not discontinued from the study treatment. Patients who discontinue from study treatment early will remain in the study and follow the procedures described in Section 5.5.9. Nevertheless, the data on and post the date of the last treatment + 4 weeks will be treated as missing in the pr imary anal ysis. The ISS7 is the sum of the average daily itch scores over 7 days each week. The daily itch scores are calculated based on daily eDiary entries for itch. The daily itch score is then calculated as the average of the morning and evening itch scores. When either the morning or evening score is missing, the non-missing itch score for that day (morning or evening )will be used as the daily score. When one or more of the daily itch scores are missing, the following principles will be applied to h andle the missing data: If a patient has at least 4 non -missing daily itch scores within the 7 days prior to the study visit, the ISS7 score is calculated as the sum of the available eDiary itch scores in that week, divided by the number of days that have a non-missing diary itch score, multiplied by 7. If there are less than 4 non -missing daily itch scores within the prior 7 days, then the ISS7 score is missing for the week. 9.4.4 Sensitivity analy ses The impact of missing data on the primary analysis results will be assessed by repeating the analysis using different missing data assumptions to handle missing data. The supportive analyses may include, but are not limited to: An analysis of covariance ( ANCOVA ) model with missing Week 12 itch scores imputed by carrying forward the patients’ baseline scores (BOCF ). The ANCOVA model would include treatment group asafactor, and baseline score as a covariate. An ANCOVA model with m issing Week 12 itch scores imputed by carry ing forward the patients’ last non -missing weekl y score (LOCF ).The ANCOVA model would include treatment group as factor s, and baseline score as a covariate. Jump -to-Reference (J2R) multiple imputation approach 9.5 Analysis of secondary variables 9.5.1 Efficacy variables All of the secondary efficacy variab les will be analy zed using the FAS unless otherwise specified."
57,page_57,"Nova rtis Confidential Page 58 Clinical Trial Protocol (Version 00 ) Protocol No. CIGE025E2305 Testing strategy The following primary and secondary hypotheses will be included in the testing strategy . To ensure the famil y-wise type I error rate (α)is kept at an overall level of less than 5%, a flexible gate-keeping procedure (Bretz et al 2009) will be employ ed as described below. The procedure allows the type-one error rate associated with a rejected hypothesis to be reallocated among the remaining ( un-rejected )hypothesis tests according to a set of pre- specified rules. The hypotheses are organized to describe the order in which different sets of hypotheses will be tested. Primary objectives (as described in Section 9.4): H1: Omalizumab 300mg is not different to placebo with respect to change from baseline in ISS7 (weekly itch severity score )at Week 12 H2: O malizumab 150mg is not different to placebo with respect to change from baseline in ISS7 (weekly itch sever ity score )at Week 12 Secondary objectives: H3: O malizumab 300mg is not different to placebo with respect to change from baseline in UAS7 (weekl y urticaria activity score )at Week 12 H4: O malizumab 150mg is not different to placebo with respect to change from baseline in UAS7 (weekl y urticaria activity score )at Week 12 H5: O malizumab 300mg is not different to placebo with respect to change from baseline in NHS7 (weekl y number of hives score )at Week 12 H6: O malizumab 150mg is not different to placebo with respect to change from baseline in NHS7 (weekl y number of hives score )at Week 12 H7: O malizumab 300mg is not different to placebo with respect to the percentage of patients with UAS7 ≤6 response at Week 12 H8: O maliz umab 150mg is not different to placebo with respect to the percentage of patients with UAS7 ≤6 response at Week 12 H9: Omalizumab 300mg is not different to placebo with respect to the percentage of patients with UAS7 =0 response at Week 12 H10: Omalizu mab 150mg is not different to placebo with respect to the percentage of patients with UAS7 =0 response at Week 12 H11: Omalizumab 300mg is not different to placebo with respect to the percentage of patients with ISS7 MID response at Week 12 H12: Omalizumab 150mg is not different to placebo with respect to the percentage of patients with I SS7 MID response at Week 12 H13: Omalizumab 300mg is not different to placebo with respect to change from baseline in overall DLQI score at Week 12 H14: Omalizumab 150mg is not different to placebo with respect to change from baseline in overall DLQI score at Week 12"
58,page_58,"Nova rtis Confidential Page 59 Clinical Trial Protocol ( Version 00 ) Protocol No. CIGE025E2305 H15: Omalizumab 300mg is not different to placebo with respect to the time to ISS7 MID during the randomized treatment epoch H16: Omalizuma b 150 mg is not different to placebo with respect to the time to ISS7 MID during the randomized treatment epoch The graphical approach of (Bertzet al2009 )for sequentially rejective testing procedures is used to illustrate the testing strategy in Figure 9 -1. Figure 9-1 Testing strategy for primary and secondary endpoints Note: As shown in the above graph, initially each H1and H2 will be assigned α/2 to test the individual hy potheses simultaneously and move forward."
59,page_59,"Nova rtis Confidential Page 60 Clinical Trial Protocol (Version 00 ) Protocol No. CIGE025E2305 The family -wise error rate will be set to α =5% (2-sided )and will be controlled using the proposed hierar chical testing strategy as illustrated in Figure 9 -1. First, each of the hypotheses ( H1and H2)for the primary objective (based on change from baseline in ISS7 at Week 12)for omalizumab 300mg and 150mg versus placebo will be tested simultaneously at α/2. If at least one of H1and/or H2isrejected, then H3and/or H 4, respectivel y, will be tested at α/2. If at least one of H3and/or H4isrejected, then H5and/or H6, will be tested, respectivel y. A similar process applies until H15and H16. Once all hypotheses for anomalizumab dose are rejected, then the respective α/2 can be passed on to the other dose’s hypotheses, if they are not alread y rejected at α/2. In the description above, rejection of a hypo thesis refers to rejection of the two-sided hypothesis; however the significance level of a rejected hypothesis is only passed on according to the graphical procedure for the test of another hy pothesis if the treatment effect is in favor of omalizumab . Change from baseline in weekly urticarial activity score ( UAS7)at Week 12 The urticaria activity score (UAS )is a composite score (itch severit y score and number of hives score )described inSection 6.4.1.1. For each of the morning and evening UAS score, it is calculated as the sum of the itch severit y score and number of hives score according to eDiary entries. The daily UASis the average of the morning and evening UAS scores , and UAS7 is the sum of daily UAS scores over 7 day s. The missing data will be handled in the same way as described in Section 9.4.3 . Treatment comparisons of 300mg vs placebo ( H3)and 150mg vs placebo ( H4)in change from baseline to Week 12 in the UAS7 will be made using an MMRM model with similar terms as the primary analy sis but baseline UAS7 as a covariate (Refer to Section 9.4.2 ). Change from baseline in weekly number of hives score (NHS7 )at Week 12 The weekl y number of hives score (NHS7 )will be handled using the same principles as described for the primary endpoint in Section 9.4.1 and Section 9.4.3. Treatment comparisons of 300mg vs placebo ( H5)and 150mg vs placebo (H 6)in change from baseline to Week 12 in the NHS7 will be made using an MMRM model with similar terms as the primary analy sis but baseline NHS7 as a covariate (Refer to Section 9.4.2 ). Percentage of patients with UA S7≤6 at Week 12 Treatment comparisons of 300mg vs placebo ( H7)and 150mg vs placebo (H 8)in the percentage of patients with UAS7 ≤ 6 at Week 12 will be made using a logistic regression model with tr eatment group as a factor and baseline UAS7 as a covariate. A patient with missing data at Week 12 will be imputed as a responder if the patient was a responder at Week 10 and Week 11, otherwise as a non -responder."
60,page_60,"Nova rtis Confidential Page 61 Clinical Trial Protocol (Version 00 ) Protocol No. CIGE025E2305 Percentage of patients with UA S7=0 at Week 12 Treatment comparisons of 300mg vs placebo (H9)and 150mg vs placebo (H10)in the percentage of patients with UAS7 = 0 at Week 12 will be made using a logistic regression model with treatment group as a factor and baseline UAS7 as a covariate. A patient with missing data at Week 12 will be imputed as a responder if the patient was a responder at Week 10 and Week 11, otherwise as a non -responder. Percentage of patients with ISS7 MID response at Week 12 The I SS7MID response is defined as a reduction from baseline in ISS7of ≥5 points. Treatment comparisons of 300mg vs placebo (H 11)and 150mg vs placebo (H 12)in the percentage of patients with ISS7MID response at Week 12 will be made using a logistic regression model with treatment group as a factorand baseline ISS7 as a covariate. A patient with missing data at Week 12 will be imputed as a responder if the patient was a responder at Week 10 and Week 11, otherwise as a non -responder. Change from baseline in overall DLQI at Week 12 DLQI is a PRO instrument, described in Section 6.4.2.1. An overall score will be calculated according to the scoring manual given inAppendix 3 . The baseline and up to Week 12 overall DLQI scores will be derived from the questionnaire s assessed at the Day 1 and up to Week 12 visits . Treatment comparisons of 300mg vs placebo ( H13)and 150mg vs placebo (H14)in change from baseline to Week 12 in overall DLQI score will be made using an MMRM model with similar terms as primary anal ysis but baseline DLQI as a covariate (Refer to Section 9.4.2). Time to ISS7 MID response during the randomized treatment epoch The ISS7MID response is defined as a reduction from baseline in ISS7of ≥5 points. Time to ISS7 MID response is the time (in weeks )from the date of the first dose to the date where ISS7 MID response is first achieved during the randomized treatment epoch. If no ISS7 MID response is achieved during the randomized treatment period , the patient will be treated as censored at the last dose date + 28 day s – 1. Treatment comparisons of 300mg vs placebo (H15)and 150mg vs placebo (H 16)will be performed using aCox propor tional hazard (PH)model with treatment group as a factor and baseline ISS7 as a covariate . The ratio of event rate and 95% CI will be reported. Kaplan -Meier analysis stratified by treatment group will be also presented with log-rank test and display ed gr aphically . 9.5.2 Safety variables All safet y evaluations will be performed on the safety set (SAF)."
61,page_61,"Nova rtis Confidential Page 62 Clinical Trial Protocol (Version 00 ) Protocol No. CIGE025E2305 Adverse events All the AEs occurring after providing written informed consent will be recorded on the Adverse Event eCRF page. AEs starting on or after the first dose of study treatment or events present prior to the first dose of study treatment but increased in severit y based on preferred term will beclassified as treatment emergent AEs. Overall AEs, SAEs, AEs by severit y will be also summarized for each epoch (randomized -treatment and post-treatment follow -up) when necessary . Non-treatment emergent AEs (occurring after providing written informed consent but before first dose of study treatment )will not be summarized but listed only . Treatment emergent AEs will besummarized by presenting, for each treatment group, the number and percentage of patients having any AE, having an AE in each primary system organ class and having each individual AE (preferred term ). Summaries will be also presented for treatment emer gent AEs by severit y and for study treatment related AEs. If a patient reported more than one AEwith the same preferred term, the AEwith the greatest severit y will be presented. If a patient reported more than one AEwithin the same primary system organ class, the patient will be counted only once with the greatest severity at the system organ class level, where applicable. Separate summaries will be provided for death, serious adverse event, and adverse events leading to discontinuation. Treatment emerge nt AEs of special interest for omalizumab treatment will be also summarized. AEs of special interest for omalizumab treatment will be specified as compound- level risk factors defined in the Case Retrieval Strategy . Summary tables that present numbers and percentages of patients with the AEs of special interest will be presented bystandardized MedDra Query (SMQ ) (if applicable ), preferred term and treatment. In addition, the hepatic disorders events will be tabulated by latent TB at baseline ( Yes/No ). Labor atory data The summary of laboratory evaluations will be presented for three groups of laboratory tests (hematology , serum chemistry and urinal ysis). Descriptive summary statistics for the change from baseline to each study visit will be presented. These descriptive summaries will be presented by test group, laboratory test and treatment group. Change from baseline will only be summarized for subjects with both baseline and post baseline values . The hepatic -related laboratory tests will also be tabulated by latent TB at baseline (Yes/No ) . Anti-omalizumab antibody A summary of anti -omalizumab antibodies will be provided. Vital signs Analy sis of the vital sign measurements using summary statistics for the change from baseline for each post-baseline visit will be performed. These descriptive summaries will be presented by vital sign and treatment group. Change from baseline will only be summarized for subjects with both baseline and post -baseline values. Subjects with notable vital signs as defined below will be listed."
62,page_62,"Nova rtis Confidential Page 63 Clinical Trial Protocol (Version 00 ) Protocol No. CIGE025E2305 Hypertension (systolic blood pressure of ≥ 140 mmHg and/or diastolic blood pressure of ≥ 90 mmHg )or hy potension (systolic blood pressure or < 90 mmHg and/or diastolic blood pressure of < 60 mmHg ). Pulse rate below 60 bpm (bradycardia )or above 100 bpm (tachycardia ) Other Healthcare utilization (calling a doctor, nurse, or nurse practitioner )based onpatient daily diary data will be summarized for each treatment group. For patients reporting angioedema, the action (s)taken in response to their angioedema based on patient daily diary data will be summarized for each treatment group. 9.5.3 Resource utilization Not applicable . 9.5.4 Biomarkers Not applicable. 9.5.5 DNA Not applicable."
63,page_63,Nova rtis Confidential Page 64 Clinical Trial Protocol (Version 00 ) Protocol No. CIGE025E2305
64,page_64,Nova rtis Confidential Page 65 Clinical Trial Protocol (Version 00 ) Protocol No. CIGE025E2305
65,page_65,"Nova rtis Confidential Page 66 Clinical Trial Protocol (Version 00 ) Protocol No. CIGE025E2305 9.7 Interim analyses No interim analysisis planned in this study . 9.8 Sample size calculation The study is sized to ensure sufficient power to demonstrate meaningful efficacy based on the data from the full analy sis set. In addition, for registration of a biologic compou nd the China health authority (China Food and Drug Administration , CFDA) requires at least 300 patients to be treated in the test drug as the minimum for safet y evaluation. Assuming 10% dropout rate by week 12, the study will randomize 420 patients in a ratio of 2:2:1 to omalizumab 300 mg, omalizumab 150 mg, and placebo to ensure 375 patients completing Week 12 with 300 patients in the two omalizumab dose groups."
66,page_66,"Nova rtis Confidential Page 67 Clinical Trial Protocol (Version 00 ) Protocol No. CIGE025E2305 The below power evaluation for the planned hypothesis tests is based on a sample size of 375 (2:2:1 ) patients who complete 12 weeks of treatment duration. The powers are examined according to the hierarchy order of the multiplicity type I error control plan with the overall alpha level controlled at 0.05 (2- sided )as outlined in Figure 9-1. It is assumed Study E2305 will repeat the performance of the previous pivotal studies (Q4881g, Q4882g, and E2306 ). Except for ethnicit y, these 3 studies have a similar patient population with consistent results for the prim ary and secondary endpoints. There is no statistical evidence suggesting heterogeneity among the studies. A meta -analy sis with fixed -effects model was performed based on summary data from these studies to combine the estimates of the treatment effect and standard deviation (SD). The obtained pooled estimates on the treatment effect size and SD are then used as the assumed values for the alternative hypotheses to evaluate the power for each endpoint. To understand the impact of the strength of dependency bet ween endpoints on the power, the power was evaluated under 3 scenarios of correlation (0, 0.5, 0.9 ), i.e. completely independency , moderate dependency , and strong dependency . The results are summarized in Table 9 -1. For theprimary endpoint (change from baseline weekl y itch score at Week 12), the study will offer a power of > 99.9% to detect a difference of 4.73 between 300 mg and placebo with the assumed SD of 5.28 a power of > 93% to detect a difference of 2.73 between 150 mg and placebo with the assumed SD of 5.55 The power was evaluated for the primary and secondary endpoints as a whole according to the testing strategy defined in Section 9.5.1 (Figure 9-1) using the gMCP package in the R software. According to Table 9 -1, the power evaluation is summarized as follows. The power for 300 mg is maintained at nearly 95% and above for all testing hypotheses regar dless of the strength of dependency between endpoints. The power for 150 mg is at least 80% for the testing hypotheses up to the endpoint of percentage of patients with UAS7 ≤ 6 at Week 12. The power for the rest of endpoints is decreased to 65% and below , and can be as low as 18% if the dependency between endpoints is none. By reviewing and using clinical data from previous studies in the power assessment for the targeted hypothesis tests for the current study , the total sample size of 420 (including 10% dropout )with 2:2:1 assignment ratio is considered appropriate to allow sufficient power to achieve the primary objective and all the first four secondary objectives for both 300 mg and 150 mg. The study also has high power to achieve the last four second ary objectives for 300 mg, although the power is < 65% and below for 150mg. Table 9 -1 Power analy sis of primary and key secondary endpoints EndpointHypo- thesisComparisonParameter assumptions1Power2 Correlation between endpoints"
67,page_67,"Nova rtis Confidential Page 68 Clinical Trial Protocol (Version 00 ) Protocol No. CIGE025E2305 None (0)Moderate (0.5)Strong (0.9) Change from baseline in ISS7 at W12H1300 mg vs PlaceboΔ=4.73 SD=5.28>0.99 9>0.999 >0.999 H2150 mg vs PlaceboΔ=2.73 SD=5.550.933 0.931 0.932 Change from baseline in UAS7 at W12H3300 mg vs PlaceboΔ=11.16 SD=11.54>0.99 9>0.999 >0.999 H4150 mg vs PlaceboΔ=6.31 SD=11.840.899 0.906 0.925 Change from baseline in NHS7 at W 12H5300 mg vs PlaceboΔ=6.22 SD=6.82>0.99 9>0.999 >0.999 H6150 mg vs PlaceboΔ=3.52 SD=6.770.859 0.880 0.917 % of patients with UAS7 ≤6 at W12H7300 mg vs PlaceboLog OR=2.09 SD=2.48 (~ p 300=61%, p 0=16% )>0.99 9>0.999 >0.999 H8150 mg vs PlaceboLog OR=1.32 SD=2.46 (~ p 150=41%, p 0=16% )0.830 0.864 0.914 % of patients with UAS7 = 0 at W 12H9300 mg vs PlaceboLog OR=2.27 SD=3.46 (i.e. p 300=41%, p 0=7%)0.992 0.992 0.991 H10150 mg vs PlaceboLog OR=1.21 SD=3.63 (~ p 150=19%, p 0=7%)0.540 0.616 0.654 % of patients with ISS7 MID at W12H11300 mg vs PlaceboLog OR=1.57 SD=2.34 (~ p 300=81%, p 0=47% )0.986 0.986 0.989 H12150 mg vs PlaceboLog OR=0.78 SD=2.09 (~ p 150=65%, p 0=47% )0.408 0.537 0.631 Change from baseline in Overall DLQI at W12H13300 mg vs PlaceboΔ=3.55 SD=5.860.965 0.969 0.977 H14150 mg vs PlaceboΔ=1.91 SD=6.250.237 0.404 0.536 Time to ISS7 MIDH15300 mg vs PlaceboLog HR=0.7 SD=1.14 (~ S 300=6%, S 0=25% )0.947 0.955 0.970 H16150 mg vs PlaceboLog HR=0.43 SD=1.15 (~ S 150=12%, S 0=25% )0.179 0.372 0.530"
68,page_68,"Nova rtis Confidential Page 69 Clinical Trial Protocol (Version 00 ) Protocol No. CIGE025E2305 EndpointHypo- thesisComparisonParameter assumptions1Power2 Correlation between endpoints None (0)Moderate (0.5)Strong (0.9) 1 Parameter assumptions are based on a meta -analysis of Studies Q4881g, Q4882g, and E2306 Δ= Difference; OR=Odds Ratio; HR: Hazard Ratio (i.e. ratio of event rate ) p300, p150, p0: the probability of an event occurrence at W eek 12 for Omalizumab 300mg, 150mg, and placebo S300, S150, S0: the probability of not having an event at and prior to Week 12 for Omalizumab 300mg, 150m g, and placebo SD= Standard deviation for the data either normally distributed or on the scale with a normal approximation, e.g. logit (p)for binary data and log -log(S)for time -to-event data 2 Power is calculated based on the total sample size of 420 assigned to treatment group 300 mg, 150 mg and placebo in ratio of 2:2:1 with 10% dropout rate during 12 weeks of treatment period, according to the hierarchy order of the multiplicity T ype I error control scheme with overall alpha level controlled at 0.05 (2- sided ). 10 Ethical considerations 10.1 Regulatory and ethical compliance This clinical study was designed and shall be implemented, executed and reported in accordance with the ICH Harmonized Tripartite Guidelines for Good Clinical Practice, with applicable local regulations (including European Directive 2001/20/EC, US CFR 21, and Japanese Ministry of Health, L abor, and Welfare ), and with the ethical principles laid down in the Declaration of Helsinki. 10.2 Informed consent procedures Eligible patients/subjects may only be included in the study after providing written (witnessed, where required by law or regulation ), IRB/IEC -approved informed consent, or, if incapable of doing so, after such consent has been provided by a legally acceptable representative (s)of the patient. In cases where the patient’s representative gives consent, the patient must be informed about the study to the extent possible given his/her understanding. If the patient is capable of doing so, he/she must indicate assent by personally signing and dating the written informed consent document or a separate assent form. Informed consent must be obtained before conducting any study -specific procedures (e.g. all of the procedures described in the protocol ). The process of obtaining informed consent must be documented in the patient source documents. Novartis will provide to investigators in a separate document a proposed informed consent form that complies with the ICH GCP guideline and regulatory requirements and is considered appropriate for this study . Any changes to the proposed consent form suggested by"
69,page_69,"Nova rtis Confidential Page 70 Clinical Trial Protocol (Version 00 ) Protocol No. CIGE025E2305 the invest igator must be agreed to by Novartis before submission to the IRB/IEC, and a copy of the approved version must be provided to the Novartis monitor after IRB/IEC approval. Women of child bearing potential must be informed that taking the study treatment may involve unknown risks to the fetus if pregnancy were to occur during the study and agree that in order to participate in the study they must adhere to the contraception requirement for the duration of the study . If there is any question that the patient will not reliably compl y, they must not be entered in the study . 10.3 Responsibilities of the investigator and IRB/ IEC Before initiating a trial, the investigator/institution must obtain approval/favorable opinion from the Institutional Review Board/Independent Ethics Committee (IRB/IEC )for the trial protocol, written informed consent form, consent form updates, subject recruitment procedures (e.g., advertisements) and any other written information to be provided to patients/subjects. Prior to study start, the investigator is required to sign a protocol signature page confirming his/her agreement to conduct the study in accordance with these documents and all of the instructions and procedures found in this protocol and to give access to all relevant data and records to Novartis monitors, auditors, Novartis Quality Assurance representatives, designated agents of Novartis, IRBs/IECs, and regulatory authorities as required. If an inspection of the clinical site is requested by a regulatory authority , the investigato r must inform Novartis immediately that this request has been made. 10.4 Publication of study protocol and results The key design elements of this protocol will be posted in a publicly accessible database such as clinicaltrials.gov. In addition, upon study completion and finalization of the study report the results of this trial will be either submitted for publication and/or posted in a publicly accessible database of clinical trial results. 10.5 Qualit y Control and Quality Assurance Novartis maintains a robust Quality Management (QM)system that includes all activities involved in quality assurance and qualit y control, including the assignment of roles and responsibilities, the reporting of results, and the documentation of actions and escalation of issues identified during the review of qualit y metrics, incidents, audits and inspections. Audits of investigator sites, vendors, and Novartis sy stems are performed by Novartis Pharma Auditing and Compliance Qualit y Assurance (CQA ), a group independent from those involved in conducting, monitoring or performing quality control of the clinical trial. The clinical audit process uses a knowledge/risk based approach. Audits are conducted to assess GCP compliance with global and local regulatory requirements, protocols andinternal SOPs, and are performed according to written Novartis processes. 11 Protocol adherence This protocol defines the study objectives, the study procedures and the data to be collected on study participants. Additional assessments required to ensure safety of patients/subjects"
70,page_70,"Nova rtis Confidential Page 71 Clinical Trial Protocol (Version 00 ) Protocol No. CIGE025E2305 should be administered as deemed necessary on a case by case basis. Under no circumstances is an investigator allowed to collect additional data or conduct any additional procedures for any research related purpose involving any investigational drugs under the protocol. Investigators ascertain they will apply due diligence to avoid protocol deviations. If an investigator feels a protocol deviation would improve the conduct of the study this must be considered a protocol amendment, and unless such an amendment is agreed upon by Novartis and approved by the IRB/IEC and health authorities, where required, it cannot be implemented. 11.1 Protocol amendments Any change or addition to the protocol can onl y be made in a written protocol amendment that must be approved by Novartis, health authorities where required, and the IRB/IEC prior to implementation. Only amendments that are intended to eliminate an apparent immediate hazard to patients/subjects may be implemented immediately provided the health authorities are subsequently notified by protocol amendment and the reviewing IRB/IEC is notified. Notwithstanding the need for approval of formal protocol amendments, the investigator is expected to take any immediate action required for the safet y of any patient included in this study , even if this action represents a deviation from the protocol. In such cases, the reporting requirements identified in Section 7 Safety Monitoring must be followed. 12 References References are available upo n request Bretz F, Maurer W, Brannath W ,et al. (2009) A graphical approach to sequentially rejective multiple test procedures. Stat Med; 284 : 586-604. Won -Sun Choi, Eun -Soo L im, Ga -Young Ban, et al. (2016) Disease -specific impai rment of the quality of lif e inadult patients with chronic spontaneous urticaria. Korean J I ntern Med ; Jun 1. [ Epub ahead of print ] Dohert y SD, Van Voorhees A, Lebwohl MG, et al. (2008) National Psoriasis Foundation consensus statement on screening for latent tuberculosis infection in patients with psoriasis treated with s ystemic and biologic agents. J Am Acad Dermatol; 59:209 -17. Fiebiger E, Maurer D, Holub H, et al. (1995) Serum IgG autoantibodies directed against the alpha chain of Fc epsilon RI: a selective marker and pathogenetic factor for a distinct subset of chronic urticaria patients? J Clin I nvest; 96:2606 -12. Finlay AYandKhan GK (1994) Dermatology Life Quality Index (DLQI ): asimple practical measure for routine clinical use. Clin Exp Dermatol; 19:210 -6. Fukuda S, Shimoy ama T, Umegaki N, et al. (2004 )Effect of Helicobacter pylori eradication in the treatment of Japanese patients with chronic idiopathic urticaria. J Gastroente rol; 39:827 -30. Hide MandHiragun T (2012) Japanese guidelines for diagnosis and treatment of urticaria in comparison with other countries. Allergol Int; 61 ( 4):517- 27."
71,page_71,"Nova rtis Confidential Page 72 Clinical Trial Protocol (Version 00 ) Protocol No. CIGE025E2305 Kaplan AP, Joseph K, Maykut RJ, et al. (2008 )Treatment of chronic autoimmune urticaria with omalizumab. J Allergy Clin I mmunol; 122:569 -73. Kaplan APand Greaves M (2009) Pathogenesis of chronic urticaria. Clin Exp Allergy ; 39:777 - 87. Luo Jie, Song ZQ, Zhong H, et al. (2011) Clinical epidemiological characteristics of chronic urticaria: report of 535 cases . Journal of Third Military Medical University ; 33(22) :2421 - 24. Mallinckrodt CH, Scott CW,David SR ( 2001) Accounting for dropout bias using mixed - effects models. Journal of Biopharmaceutical Statistics; 119-21. Manuel O, Kumar D (2008) QuantiFERON -TB Gold assay for the diagnosis of latent tuberculosis infection. Expert Rev Mol Diagn; 8:247 -56. Mathias SD, Dreskin SC, Kaplan A, et al. (2010) Development of a daily diary for patients with chronic idiopathic urticaria. Ann Allergy Asthma I mmunol; 105:142-8. Mathias SD, Crosby RC, Zazzali JL, et al. (2012 )Evaluating the minimally important difference of the urticaria activity score and other measurements of disease activity in patients with chronic idiopathic urticaria. Ann Allergy Asthma Immunol; 108:20 -24. Maurer M, Weller K, Bindslev -Jensen C, et al. (2011) Unmet clinical needs in chronic spontaneous urticaria. A GA2LEN task force report. Allergy ; 66:317 - 30. Mlynek A, Zalewska -Janowska A, Martus P, et al (2008) How to assess disease activity in patients with chronic urticaria? Allergy ; 63:777 -80. Rubin DB (1976) Inference and Missing Data. Biometrika ;63:581 -92. Shikiar R, Harding G, Leah y M, et al. (2005) Minimal Important Difference (MID )of the Dermatology Life Quality Index (DLQI): results from patients with chronic idiopathic urticaria. Health Qual Life Outcomes; 3:36. Tong LJ, Balakrishnan G, Kochan JP, et al. (1997 )Assessment of autoimmunity inpatients with chronic urticaria. J Allergy Clin Immunol; 99:461 -5. World Health organiza tion (2015) Guidelines on the management of latent tuberculosis infection. World Health organization (2015) Global tuberculosis report 2015. Zhong H, Song Z, Chen W, et al. ( 2014) Chronic urticaria in Chinese population: a hospital - based multicenter epidemiological study . Allergy ; 69:359 - 64. Zuberbier T, Asero R, Bindslev- Jensen C, et al. (2009) EAACI/GA2LEN/EDF/WAO guideline: definition, classification and diagnosis of urticaria. Allergy ;64:1417 - 26. Zuberbier T, Aberer W, Asero R, , et al. (2014) EAACI /GA2LEN/EDF/WAO guideline for definition, classification, diagnosis, and management of urticaria: the 2013 revision and update. Allergy ; 69:868 - 87. Zweiman B, Valenzano M, Atkins PC(1998) Modulation of serum histamine releasin g activity in chronic idiopathic urticaria. Immunopharmacology ; 39:225 - 34."
72,page_72,"Nova rtis Confidential Page 73 Clinical Trial Protocol (Version 00 ) Protocol No. CIGE025E2305 13 Appendi ces 13.1 Appendix 1: Clinically notable laboratory values and vital signs The following criteria will be used to define expanded limit and notable abnormalities. Hematology value Platelet count: ≤ 100,000 / μL No specific action is pre-defined within this protocol to respond to specific abnormal laboratory values, as it will be decided by the investigator /qualified site staff whether and whic h specific action needs to be taken to respond to any abnormal values, taking into account the overall status of the subjects. For all other laboratory assessments, the Central Laboratory will flag laboratory values falling outsides of the normal ranges on the Central Laboratory Report (which the investigator should review and sign off)and the investigator will report any values considered clinically significant in the CRF. Vital signs Notable values of vital signs are described in Section 9.5.2 . 13.2 Appendix 2 Blood log Table 13-2 Blood log for immunogenicity Immunogenicity Matrix Serum Visit Sample No. Volume (mL) Visit 101 (pre-dose ) 401 2 Visit 299 402 2 Sub total (mL) 4"
73,page_73,"Nova rtis Confidential Page 74 Clinical Trial Protocol (Version 00 ) Protocol No. CIGE025E2305 13.3 Appendix 3 Dermatology Life Quality Index (DLQI ) questionnaire DERMATOLOGY LIFE QUALITY INDEX DLQI Hospital No: N/A Date: Name: N/A Score: Address: N/A Diagnosis: The aim of this questionnaire is to measure how much your skin problem has affected your life OVER THE LAST WEEK. Please tick one box for each question. 1. Over the last week, how itchy , sore, Very much  painful or stinging has your skin Alot  been? A little  Not at all  2. Over the last week, how embarrassed Very much  or self conscious have you been because A lot  of your skin? A little  Not at all  3. Over the last week, how much has your Very much  skin interfered with you going A lot  shopping or looking after your home or A little  garden ? Not at all  Not relevant  4. Over the last week, how much has your Very much  skin influenced the clothes A lot  you wear? A little  Not at all  Not relevant  5. Over the last week, how much has your Very much  skin affected any social or A lot  leisure activities? A little  Notat all  Not relevant  6. Over the last week, how much has your Very much  skin made it difficult for A lot  you to do any sport ? A little  Not at all  Not relevant  7. Over the last week, has your skin prevented Yes "
74,page_74,"Nova rtis Confidential Page 75 Clinical Trial Protocol (Version 00 ) Protocol No. CIGE025E2305 you from work ingor studying ? No  Not relevant  If ""No"", over the last week how much has A lot  your skin been a problem at A little  work or studying ? Not at all  8. Over the last week, how much has yo ur Very much  skin created problems with your A lot  partner or any of your close friends A little  or relatives ? Not at all  Not relevant  9. Over the last week, how much has your Very much  skin caused any sexual A lot  difficulties ? A little  Not at all  Not relevant  10. Over the last week, how much of a Very much  problem has the treatment for y our A lot  skin been, for example by making A little  your home messy, or by taking up time? Not at all  Not relevant  Please check you have answered EVERY question. Thank you. AY Finlay, GK Khan, April 1992 www.dermatology.org.uk , this must not be copied without the permission of the authors."
